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Abstract 
Capsaicin, the primary active constituent of chilli, has various recognised potential health benefits 
including analgesia but has also been investigated in studies focusing on obesity, hypertension, 
glucose impairment and altered blood lipid profiles. These physiological changes are the clustering 
of risk factors comprising the metabolic syndrome, which increases the risk of developing diabetes, 
non-alcoholic fatty liver disease and cardiovascular disease. Current clinical treatments demonstrate 
poor compliance and do not target the range of risk factors. Hence, the aim of this study is to 
determine whether low-dose dietary capsaicin attenuates the cardiovascular, liver and metabolic 
changes in a diet-induced rat model that mimics the human syndrome. 8-9 weeks old normotensive 
male Wistar rats were divided into 4 groups (n=8-12). Two groups were fed a cornstarch (C) diet 
and two were fed a high-carbohydrate, high-fat (H) diet, rich in saturated and trans fatty acids and 
simple sugars, thus mimicking the westernised-diet in humans. One group of each of the two diets 
was supplemented with dietary capsaicin (CC and HC; 13.3 and 7.3 mg/kg body weight/day) as a 
treatment for the final 8 weeks of the 16 week protocol. The H diet induced obesity, hypertension, 
dyslipidaemia, cardiovascular and liver damage and glucose intolerance by week 8 of the protocol. 
HC rats showed reduced abdominal circumference (24.3±0.5 cm to
 
19.0±0.2 cm), body weight gain 
(276±36 g to 186±9 g) and plasma concentrations of triglycerides (2.1±0.2 mmol/L
 
to 1.4±0.2 
mmol/L) compared to H rats. Capsaicin treatment reduced inflammation within the heart and liver, 
decreased hepatic fat vacuole enlargement and reduced cardiac collagen deposition. This decreased 
ventricular stiffness and further, reversed hepatic dysfunction by normalising liver damage in HC 
rats. Endothelial dysfunction and hypertension were normalised in HC rats, following a decrease in 
systolic blood pressure (153±2 mmHg to 132±2 mmHg). Finally, low-dose dietary capsaicin 
reversed glucose intolerance in H-fed rats. Hence, the present findings suggest that low-dose dietary 
capsaicin could be a potential therapeutic option for the reduction of obesity and metabolic 
syndrome in humans. 
Key words – Capsaicin, transient receptor potential vanilloid 1(TRPV1), metabolic syndrome, 
cardiovascular, obesity, glucose, triglycerides, non-alcoholic fatty liver disease  
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Chapter 1:  Introduction and literature review 
1.1 Metabolic syndrome and obesity 
Metabolic syndrome is not described as a disease itself but rather as a constellation of symptoms 
that typically occur together (Harris 2013). There has been variation in both the definition and 
diagnosis of metabolic syndrome, but there is now international consensus that metabolic syndrome 
must constitute the presence of at least three of the following five conditions: central obesity, 
hypertension, decreased blood high density lipoproteins (HDL), elevated fasting glucose and 
elevated blood triglycerides concentrations (Harris 2013). These physiological changes enhance the  
risk of developing cardiovascular disease and type 2 diabetes and related complications, such as 
chronic renal disease (Harris 2013). Table 1 provides the criteria used by the Royal Australian 
College of General Practitioners (RACGP) in determining the diagnosis of metabolic syndrome in 
Australians.  
Table 1: RACGP criteria for metabolic syndrome diagnosis. 
Measure  Categorical Cut Point  
Elevated waist 
circumference (measure of 
central obesity) 
Population specific. 
However figure for Caucasian and Indigenous Australians: 
≥102 cm in males and ≥88 cm in females 
Elevated triglyceride levels ≥1.7 mmol/L 
Reduced HDL <1.0 mmol/L in men, <1.3 mmol/L in women 
Elevated blood pressure ≥130 systolic or ≥85 diastolic 
Elevated fasting glucose >5.5 mmol/L 
Reference:  (Harris 2013) – modified. 
The RACGP, using the criteria listed in Table 1, indicate that 20% of Australians have been 
diagnosed with metabolic syndrome since 2004 (Harris 2013). Furthermore, the RACGP identify 
obesity as the predominant factor leading to the metabolic syndrome diagnosis (Harris 2013). 
Obesity is one of the most rapidly-escalating epidemics faced by global public-health systems, in 
particular, those belonging to developed westernised societies, such as Australia. In the 1970s, 
overweight and obesity was uncommon with less than 15% of Australians being diagnosed in this 
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category (Hayes et al. 2017). By 1995, the rate of overweight and obesity had increased to 
approximately 20% and is expected to increase to 35% by 2025 (Tolhurst et al. 2016; Hayes et al. 
2017). However, Australia currently possesses the highest incidence of overweight and obesity 
worldwide, affecting 63.4% of adults and 29.5% of people aged less than seventeen (Grima & 
Dixon 2013; Tolhurst et al. 2016). Additionally, 44.5% of adults and between 70.1-91.7% of people 
aged 17 or under do not meet the minimum daily physical activity requirements. More than 40% of 
the nation acquire their daily energy intake from ‘junk’ food, which is described as a westernised-
diet high in both saturated fats and simple carbohydrates and, therefore, hyper-caloric (Tolhurst et 
al. 2016). Obesity occurs when there is increased fat deposition following an imbalance between 
energy consumption and expenditure, where consumption exceeds expenditure. However, 
extending from this simplistic definition, obesity is a consequence of multifaceted interactions 
among genetic, environmental, socio-economic, psychological and dietary factors, thus making 
obesity a complex disease to understand and combat (Moran & Shanahan 2014; Bauer et al. 2016).  
Obesity is characterised by the presence of parameters indicating increased adiposity, low-grade 
inflammation, dysbiosis, increased neurogenic tone and hormonal imbalances (Buhmann et al. 
2014; Moran & Shanahan 2014; Bauer et al. 2016). These obesogenic factors give rise to 
comorbidities (Table 2), which in turn increase morbidity and mortality. Therefore, obesity 
determinants, as well as the associated costs, which are in excess of $8 billion per year in Australia 
alone, and unsuccessful non-invasive treatment interventions have resulted in an increase in 
research aimed at decreasing weight-loss (Grima & Dixon 2013; Buhmann et al. 2014). Moreover, 
there is poor compliance with clinical treatments such as very low energy diets and 
pharmacotherapy, thus leaving bariatric surgery as the most effective option (Grima & Dixon 
2013). Therefore, there is a need to find and evaluate effective and inexpensive treatments with 
enhanced compliance rates to decrease the momentum of this escalating problem. Since an 
increased energy intake provided by hypercaloric foods is a chief contributing factor to this 
epidemic, it seems counter-intuitive that foods may assist in combating the obesity issue. However, 
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many new drugs and pharmacological treatments are based on naturally-occurring molecules, for 
example, pseudoephedrine is a diastereomer of adrenaline while acetylsalicylic acid, or aspirin, is 
derived from the phytochemical salicylic acid extracted from the willow tree (Takenaka 2001; 
Desborough & Keeling 2017). Hence, searching for naturally-occurring bio-active compounds, 
especially within foodstuffs, is a logical step in finding effective treatments that may combat a 
range of pathological conditions including obesity.  
Table 2:  The health risks associated with overweight and obesity. 
Body System Health Risk  
Cardiovascular Stroke 
Coronary heart disease 
Cardiac failure 
Hypertension 
Gastrointestinal  Non-alcoholic fatty liver disease 
Gallbladder disease 
Pancreatic disease 
Gastro-oesophageal reflux disease 
Cancers of the bowel, oesophagus, gall bladder and pancreas 
Endocrine Non-insulin dependent diabetes mellitus 
Polycystic ovary syndrome 
Genitourinary Chronic kidney disease, which can lead to end-stage renal disease 
Cancers of the kidney and prostate 
Kidney stones 
Stress urinary incontinence (women) 
Sexual dysfunction (men) 
Pulmonary Obstructive sleep apnoea 
Obesity hypoventilation syndrome  
Asthma 
Musculoskeletal  Osteoarthritis – especially the patella 
Spinal disc disorders and lower back pain 
Disorders of soft tissue structures such as tendons, fascia and cartilage 
Foot pain 
Mobility disability   
Reproductive  Menstrual disorders 
Miscarriage and poor pregnancy outcome 
Infertility/sub-fertility 
Cancers of the breast (postmenopausal women), endometrium and ovaries 
Mental/Psychological Depression 
Eating disorders 
Reduced health-related quality of life 
Reference:  (Grima & Dixon 2013) – modified  
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1.2 Nutraceuticals and spices 
A nutraceutical is defined as any substance that is a food or part of a food and provides medical or 
health benefits, including the prevention and treatment of disease (DeFelice 1995). Traditional 
medicines, such as Chinese medicine, folklore remedies and Indian Ayurveda, which all incorporate 
the use of natural products, have been practised for millennia (WHO 2000). The use of these 
products in traditional medicines incorporates a broad range of nutraceuticals, all with different 
efficacy and varying adverse effects (WHO 2000). Historically, these medicines were often mixed 
together to form a concoction and the recipes passed on from generation to generation, with various 
doses that were deemed effective and safe in treating an ailment (WHO 2000). Currently, 
nutraceuticals are typically extracts or parts of a food that are supplemented into the diet. Dietary 
supplementation allows a concentrated quantity or dose of an extract to be consumed readily by a 
consumer (DeFelice 1995). Whilst traditional medicines may provide insight into what products 
may have been effective and at what dose, current studies aim at determining the efficacy and 
therapeutic benefits, in addition to the potential adverse effects, that a nutraceutical may deliver. 
Spices such as turmeric containing curcumin, black pepper containing piperine, garlic containing 
allicin and ginger containing zingerone and gingerol have been investigated in human and animal 
studies and acknowledged as potential nutraceuticals in the treatment of obesity and other 
symptoms of metabolic syndrome (Diwan et al. 2013; Saravanan et al. 2014; Matsumoto et al. 
2016; Panahi et al. 2016). These studies indicate that spices reduce the chronic systemic low-grade 
inflammation evident in diet-induced obese patients, which, in turn, alleviates glucose impairment, 
dyslipidaemia, hypertension, non-alcoholic liver disease and other cardiovascular disease. However, 
these studies do not investigate the long-term effects and adverse effects associated with their 
usage. Hence, further studies are needed to determine the efficacy and possible adverse effects of 
chronic treatment. Hence, this study will evaluate the primary pungent phytochemical in chilli, 
capsaicin, as a treatment for metabolic syndrome in a diet-induced obese rat model.  
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1.2 Chilli – A Brief History  
Chilli is a popular fruit commonly used to increase the flavour and piquancy of food. Evidence 
suggests chillies have been cultivated for domestic use in Mexico and Bolivia for 7000 years 
(Mortensen & Mortensen 2009; Kraft et al. 2014). In 1492, Columbus noted that the South 
Americans added chilli to food, whilst his physician noted the medicinal effects of chilli including 
folklore remedies to clean wounds, assist in bowel movement and ‘purify’ living quarters (Mózsik 
et al. 2009b; Guido et al. 2015).   
Thresh (1876) isolated capsaicin, the primary active constituent of chilli, noting that it was a white 
crystalline, odourless and volatile compound. Nelson (1919) first determined the molecular 
structure of capsaicin (Figure 1). Capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homocapsaicin 
and homodihydrocapsaicin constitute the capsaicinoids (Figure 1) (Rollyson et al. 2014). 
Capsaicinoids are exclusively produced by the Capsicum genus and are found in abundance in the 
epidermal cells of the placenta in the pod of the fruit (Zahra et al. 2016). Capsaicin constitutes 
approximately 70-80% of the capsaicinoids found in any fruit belonging to the Capsicum genus, 
thus making it the primary and most abundantly occurring capsaicinoid (Zahra et al. 2016). 
It was not until the 18
th
 and 19
th
 centuries that the chilli gained popularity in the Western world for 
its uses in folklore medicine. During this period, chilli was used predominantly as a rubefacient to 
induce analgesia and to assist in heat regulation in tropical regions (Abdel-Salam 2014; Fattori et al. 
2016). Late 19
th
 century studies with capsaicin as a pharmacological agent suggested that capsaicin 
acted on sensory nerves because capsaicin did not induce dermal vesiculation, enhanced motility of 
the gastrointestinal tract without gustatory effect and induced a fall in body temperature (Lee 1954; 
Abdel-Salam 2014). 
Ninety years later, Szolcsányi (1977) demonstrated by measuring the response of sensory fibres 
from the cat saphenous nerve that capsaicin acts as an afferent blocking agent. Capsaicin induces 
stimulation of sensory fibres initially and later causes signal blockage of the fibres as well as the 
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warmth receptors (Abdel-Salam 2014; Fattori et al. 2016). Szolcsányi (1977) also measured the 
reduction in the thermal threshold of warmth receptors when capsaicin was applied to the epidermis 
of a rat or the human tongue. Szolcsányi (1977) confirmed the findings of late 19
th
 century studies 
and also demonstrated that the response induced by capsaicin on sensory receptors was polymodal. 
This means that these sensory receptors (nociceptors) are responsive to mechanical, chemical and 
thermal stimuli (Abdel-Salam 2014). Furthermore, this started the study of capsaicin for pain relief 
due to the desensitising effect of capsaicin on mammalian polymodal nociceptors (Abdel-Salam 
2014). 
 
Figure 1:  The chemical structure of capsaicin and the capsaicinoids. Note the common vanillyl 
ring present in each capsaicinoid (Fattori et al. 2016). 
1.3 Nociception: foundations into determining the actions of capsaicin 
Nociceptors are sensory neurons that possess the ability to detect noxious and potentially noxious 
stimuli from both internal and external stimuli (Yang et al. 2016). They process this pain-related 
information into electrical signals (transduction) which are subsequently conducted to the brain 
through different signalling pathways (Handwerker 2008; Reddi et al. 2013). These neurons are 
able to detect chemical, thermal and mechanical stimuli and are, therefore, termed polymodal 
(Szolcsányi 1977; Szolcsányi 2015; Yang et al. 2016).  
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Nociceptors can alter their neurophysiological properties when they are exposed to repetitive or 
continuous noxious stimuli (Abdel-Salam 2014). Yang et al. (2016) support the landmark study of 
Szolcsányi (1977) that demonstrated the ability of nociceptors to change their sensitivity to stimuli 
such as high-dose capsaicin. The findings of this study were that repetitive applications of topical 
capsaicin to a given site could cause a decrease in neuroplasticity due to afferent nerve withdrawal 
or death, sensitisation, and/or desensitisation. Hence, since this seminal study, topical capsaicin 
applications have been used extensively to understand how this pain-related information is 
transduced from the periphery to the central nervous system.  
When capsaicin is applied topically to a given site it causes an influx of cations, such as calcium 
(Ca
2+
), through plasmalemmal channels of nociceptors (Woolf 2011). This subsequently induces 
depolarisation and the initiation of an action potential, thus stimulating an afferent message of 
perceived pain via different pathways to the brain (Iannetti et al. 2013; Dezhdar et al. 2015). These 
pathways are detailed in Figures 2 and 3. Additionally, this was the premise used for isolating and 
identifying the molecular receptor that capsaicin binds to within nociceptors (Caterina et al. 1997). 
Caterina et al. (1997) were able to see an increased expression of a functional protein and 
consequently utilised a cDNA based strategy to clone the receptor. This was subsequently validated 
by demonstrating that the receptor, Transient Receptor Potential Vanilloid 1 (TRPV1), functioned 
in vivo when a nociceptor was stimulated with capsaicin (Caterina et al. 1997). This provided a 
mechanism for how capsaicin exerted its effects on the cellular level. 
Whilst this explanation into nociception is simplistic, it can be appreciated that the central nervous 
system involvement in processing and discriminating between the types of stimuli is highly 
organised, developed and complexed and yet to be fully elucidated. Furthermore, an understanding 
of how these pathways function and how topical application of capsaicin elicits a response in the 
brain is important, as it provides the foundations of how capsaicin may link other peripheral sensory 
fibres expressing TRPV1, such as vagal afferent fibres in the gut, to the brain.  
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Figure 2:  The dorsal horn and the spinal laminae. The interactions that occur within the laminae of 
the dorsal horn are intricate and involve the primary afferent signals, interneurons and the 
descending modulatory pathway. First order neurons that terminate in the horn include the 
myelinated Aδ fibres and unmyelinated C-fibres. The C-fibres predominantly terminate in the 
second and third laminae and are responsible for transmitting the slow, diffuse, burning pain 
associated with topical capsaicin application (Hall 2015). 
 
Figure 3:  Pain transmission to the brain. Both the neospinothalamic and paleospinothalamic tracts 
are involved in the polymodal detection and processing of peripheral stimuli to the brain. The 
neospinothalamic tract is predominantly used for information being relayed by the Aδ fibres. The 
axons of these second order neurons decussate at the spinal midline and ascend to the thalamus as 
the lateral spinothalamic tract. From these thalamic areas, the signals are conducted to other basal 
areas of the brain as well as to the somatosensory cortex via third order neurons. The 
paleospinothalamic tract predominantly involves C-fibres. C-fibres synapse with dorsal horn 
interneurons, which subsequently synapse with second order neurons. The axons of the second 
order neurons mostly join the fibres from the neospinothalamic pathway. However these axons first 
pass through the anterior commissure to the opposite side of the spinal cord, proceeding upward to 
the anterolateral pathway. Majority of these neurons terminate in the reticular formation of the brain 
stem, whilst the minority of the fibres project to the thalamus (Hall 2015). 
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1.4 Transient Receptor Potential Vanilloid 1 – the capsaicin receptor 
1.4.1 Transient Receptor Potential Superfamily  
Transient Receptor Potential (TRPs) channels are among the most broad and diverse of the 
mammalian regulatory channels (O'Neill et al. 2012). Currently, there are 28 variants in the TRP 
family and these can be further divided into a variety of sub-groups depending on their function 
(Wu et al. 2010). They are non-selective cation channels located predominantly in the plasmalemma 
(Wu et al. 2010; Liao et al. 2013; Hanson et al. 2015). TRPs predominantly function as transducers 
in response to chemical and physical stimuli such as temperature, low pH, osmotic sensing, taste, 
pressure, stretch, vibration and endogenous and exogenous molecules (Wu et al. 2010; O'Neill et al. 
2012; Liao et al. 2013; Hanson et al. 2015).   
1.4.2 The Structure of TRPV1 and its agonists 
TRPV1 is one of six membrane proteins that belong to the vanilloid subgroup of the TRP 
superfamily (Hudson et al. 2016). It is a non-selective cation channel conveying polymodal 
activation by an array of mechanisms, such as mechanical stimulation, pH, endogenous and 
exogenous cannabinoids, noxious peptide toxins, heat greater than 43˚C and, most importantly, by 
vanilloids such as capsaicin (Movahed et al. 2005; Dhaka et al. 2009; Bang et al. 2010; Hakim et al. 
2015; Laing & Dhaka 2015; Zhang et al. 2015; Bae et al. 2016). Caterina et al. (1997) categorised 
TRPV1 as the capsaicin receptor, due to its activation by capsaicin and suggested that it is 
predominantly expressed in nociceptors. However, since this seminal study, it has been established 
that the TRPV1 is expressed abundantly throughout the body (Tominaga et al. 1998). Caterina et al. 
(1997) first isolated and cloned the 95 kilo Dalton protein and determined the TRPV1 gene to 
consist of 2514 nucleotides, which are subsequently transcribed and translated into a protein of 838 
amino acids. The rat and human TRPV1 receptors only differ by one amino acid and are, therefore, 
considered structurally and functionally orthologous (Hayes et al. 2000). Liao et al. (2013) used 
electron cryo-microscopy to determine the structure of the TRPV1 channel as an integral membrane 
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protein and a homo-tetramer comprised of six transmembrane α-helices (S1-S6), two cytoplasmic 
components (N-terminus and C-terminus) and a central ion pathway. Finally Liao et al. (2013) 
observed that the TRPV1 channels contained the conserved TRPV cytoplasmic ankyrin repeat 
domain, which is postulated to facilitate TRPV1 subunit association (Cao et al. 2013a) (Figure 4). 
While determining how TRPV1 subunits function upon activation has proven difficult, further 
studies are needed to elucidate its polymodal functioning, as this may provide site-specific targets 
for the treatment of many pathophysiological conditions. Additionally, solving the allosteric 
properties of TRPV1 may assist in determining how capsaicin may sensitise and desensitise a cell 
following short- and long-term low-dose capsaicin administration. 
  
Figure 4: TRPV1 topology and the critical residues involved in TRPV1 function. The TRPV1 pore 
possesses a conical shape where it is wider extracellularly compared to its intracellular passage 
opening (Abdel-Salam 2014) 
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1.4.3 Capsaicin activation of TRPV1  
When capsaicin binds to TRPV1, the channel undergoes conformational change and becomes 
permeable to cations such as Ca
2+
 (Abdel-Salam 2014). Capsaicin binds to the vanilloid-binding 
pocket, which is located on the intracellular side of the plasmalemma (Abdel-Salam 2014; Fattori et 
al. 2016; Hudson et al. 2016). Kumar et al. (2016) have postulated that the tyrosine residue Y511 is 
responsible for anchoring capsaicin to the vanilloid-binding pocket (see figure 4) thus augmenting 
the time that capsaicin complexes with TRPV1. This notion supports previous studies that suggest 
this may occur in both humans and rats as the receptors are orthologous (Cao et al. 2013a; Liao et 
al. 2013; Bae et al. 2016). However, given the other free amino acid residues, this may not be the 
only residue implicated. In any case, capsaicin allosterically alters TRPV1 properties, thus causing 
an opening of the pore and permitting cation influx, namely Ca
2+
 (Kumar et al. 2016). This influx 
causes a change in electrical properties of the cell, and induces depolarisation and increases the 
likelihood of an action potential occurring, releasing neurotransmitters such as substance P and 
calcitonin gene-related peptide (CGRP) by exocytosis (Devesa et al. 2014; Smutzer & Devassy 
2016). Substance P facilitates nociception and induces vasodilatation via its interaction with the 
neurokinin receptor (NKR) in the endothelium of blood vessels (Devesa et al. 2014; Steinhoff et al. 
2014). This also holds true for CGRP release, with the exception that it binds to calcitonin receptor-
like receptor (CALCRL) in lieu of NKR (Russell et al. 2014; Steinhoff et al. 2014). This interaction 
subsequently increases vasculature permeability and permits localised granulocyte infiltration 
(Russell et al. 2014; Steinhoff et al. 2014). Furthermore, substance P binds to NKR and CGRP 
binds to CALCRL on mast cells, and these cells in conjunction with granulocytes and surrounding 
tissue induce the release of proinflammatory mediators such as histamine, nerve growth factor, 
bradykinin, prostaglandins and adenosine tri-phosphate (ATP) (Russell et al. 2014; Steinhoff et al. 
2014; Smutzer & Devassy 2016). However, the release of CGRP and substance P decrease can also 
reduce inflammation, depending on the situation (Russell et al. 2014; Steinhoff et al. 2014). For 
example, both the sustained release and systemic administration of CGRP have been demonstrated 
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to inhibit monocyte chemoattractant protein-1 (MCP1) expression, a primary proinflammatory 
chemokine raised in various physiological conditions, such as obesity and non-alcoholic liver 
disease and inflammatory cell migration into regions such as the vasculature (Zhang et al. 2009; 
Zhang et al. 2010). Hence, further studies are needed to determine the factors that elicit both pro- 
and anti-inflammatory actions conveyed by substance P and, in particular, CGRP, as this may be 
the key in determining the anti-inflammatory properties of capsaicin upon activating TRPV1. 
1.4.4 Capsaicin-induced TRPV1 Sensitisation  
TRPV1 contains several phosphorylation sites/residues (Figure 4) (Abdel-Salam 2014). TRPV1 
phosphorylation is typically associated with sensitisation, while TRPV1 dephosphorylation is 
typically associated with desensitisation (Vriens et al. 2009; Ho et al. 2012). TRPV1 becomes 
sensitised via phosphorylation by protein kinase C (PKC) or protein kinase A (PKA), with both 
being activated by G-protein coupled receptors (GPCR) (Vriens et al. 2009; Ho et al. 2012; Smutzer 
& Devassy 2016). When capsaicin activates TRPV1 as outlined above, prostaglandin E2 and 
serotonin bind to their respective GPCR, which stimulates dissociation of the stimulatory G-protein 
subunit (Gs) from the GPCR (Vriens et al. 2009; Ho et al. 2012; Smutzer & Devassy 2016). When 
this occurs, adenylate cyclase is activated by the Gs to synthesise cyclic adenosine monophosphate 
(cAMP) (Vriens et al. 2009; Smutzer & Devassy 2016). Increased cytosolic cAMP concentrations 
signal PKA to phosphorylate TRPV1, which subsequently impedes dephosphorylation and prevents 
desensitisation, thus promoting an increased sensitivity to endogenous endovanilloids (Vriens et al. 
2009; Cao et al. 2013a; Smutzer & Devassy 2016). However, further studies, in particular in vitro 
studies, are needed to determine this mechanism. Additionally, if serotonin release is stimulated by 
capsaicin-induced TRPV1 activation, it may act to assist in appetite regulation, as increased 
systemic concentrations of serotonin have been linked to increased satiety and weight loss 
(Savastano et al. 2007; Lam et al. 2008; Halford & Harrold 2012). Hence, further studies are needed 
to determine the link between capsaicin, increased serotonin release, satiety and, therefore, energy 
intake and weight loss. 
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When bradykinin and other cytokines are released, they bind to specific GPCRs and stimulate the 
dissociation of the G-protein subunit (Gq) from the receptor (Ho et al. 2012; Smutzer & Devassy 
2016). Gq initiates the second messenger system by activating phospholipase-Cβ (PLCβ) to 
hydrolyse the phospholipid, phosphatidylinositol-4,5-bisphosphate, known as PIP2 (Morales-Lázaro 
et al. 2013; Smutzer & Devassy 2016). PIP2 is involved in cellular protein regulation, the anchoring 
of proteins to the plasmalemma and activating intracellular second messenger pathways (Morales-
Lázaro et al. 2013). PIP2 is cleaved into inositol triphosphate and diacylglycerol by PLCβ (Morales-
Lázaro et al. 2013). Free diacylglycerol has a high affinity for PKC and consequently binds to PKC, 
thus stimulating its activation (Morenilla-Palao et al. 2004; Vriens et al. 2009; Morales-Lázaro et al. 
2013). Both Vriens et al. (2009) and Por et al. (2013) suggest that TRPV1 phosphorylation by PKC 
sensitises it to chemical stimuli, thus lowering its activation threshold. This means that TRPV1 
activation by capsaicin is more likely to result in a cellular response and, therefore, the release of 
various cytokines depending on the cell type in which it is expressed. However further studies are 
needed for this hypothesis to be validated and the exact mechanism to be elucidated. These 
sequences of events may provide insight in to how low-dose capsaicin elicits different responses 
throughout the body in various pathophysiological conditions, such as obesity. For example, it 
could by hypothesised that low-dose capsaicin, which binds to TRPV1-expressing vagal afferents in 
the gut, may result in increased sensitivity of these fibres to repeated doses of capsaicin, thus 
increasing the likelihood of vagal firing. Given that vagal fibres link the gut to the brain and their 
activation is linked to increased synthesis and release of gut-peptides, such as GLP1, which 
improves glucose utilisation and increases satiety resulting in a decreased energy intake, this may 
provide a mechanism as to how capsaicin exerts its anti-obesogenic and anti-hyperglycaemic effects 
(Buhmann et al. 2014). However, further studies linking the molecular and systemic physiology are 
needed to confirm if these theories are plausible. 
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1.4.5 TRPV1 desensitisation and modulation in response to capsaicin 
Capsaicin’s use as an analgesic appears contradictory, as repeated or extended stimulation of a 
nociceptor, or more specifically, TRPV1, leads to a decrease in the pain-evoking responses and 
TRPV1 activity (Abdel-Salam 2014). This is referred to as desensitisation and provides the 
foundations of capsaicin-induced analgesia (Abdel-Salam 2014). Figure 5 demonstrates an array of 
pathophysiological conditions associated with central sensitisation. Therefore, an understanding of 
sensitising and desensitising of the TRPV1 receptors is necessary to understand possible long-term 
changes to the responses to capsaicin in metabolic syndrome.  
TRPV1 desensitisation is mediated by the influx of cytosolic Ca
2+
 from TRPV1 activation (Rohacs 
2015). Mohapatra and Nau (2005) have demonstrated that desensitisation does not occur in the 
absence of Ca
2+
. Furthermore, the homeostasis of Ca
2+
 is vital in cell survival, as increased 
intracellular Ca
2+
 concentrations are cytotoxic (Orrenius et al. 2015). Hence, TRPV1 activity must 
be regulated in order to relieve apoptosis (Orrenius et al. 2015).   
1.4.6 Dephosphorylation of TRPV1 
TRPV1 is modulated through changes in calmodulin activity (Smutzer & Devassy 2016). 
Calmodulin has a high affinity for Ca
2+
 and binds Ca
2+
 when available in excess (Rohacs 2015; 
Smutzer & Devassy 2016). Once calmodulin is activated, it stimulates the activity of calcineurin, 
which functions as a phosphatase and potentiates TRPV1 desensitisation (Rohacs 2015; Smutzer & 
Devassy 2016). While PKA phosphorylation acts to enhance TRPV1 sensitivity (Por et al. 2013), 
Mohapatra and Nau (2005) demonstrated that inhibition of calcineurin increased TRPV1 sensitivity 
to capsaicin. Calmodulin also activated Ca
2+
/calmodulin dependent kinase II (CaMKII), which has 
been postulated by Jung et al. (2004) to phosphorylate TRPV1 at PKA and PKC residues and 
potentiate TRPV1 sensitisation. However, Por et al. (2013) have demonstrated that inhibition of this 
complex does not potentiate TRPV1 desensitisation. Therefore, more studies are needed to consider 
the role of CaMKII in TRPV1 physiology.  
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Figure 5:  Pathophysiological pain conditions associated with central sensitisation that are 
relieved by capsaicin. Central sensitisation is thought to be a key phenomenon contributing to the 
development of these chronic pain conditions. Increased knowledge of sensitisation may lead to the 
development of new compounds, such as capsaicin based analogues, which can help improve the 
outcome of such conditions (O'Neill et al. 2012). 
1.4.7 PIP2-induced Desensitisation  
Another proposed, yet controversial, method that may induce TRPV1 desensitisation is through 
PIP2 hydrolysis (Smutzer & Devassy 2016). PIP2 can potentiate receptor sensitisation via PLCβ 
activation (Vriens et al. 2009; Morales-Lázaro et al. 2013). However, PIP2 cleavage by an isomer of 
PLC, PLCδ, may potentiate desensitisation (Smutzer & Devassy 2016). The increased intracellular 
concentration of Ca
2+stimulates the activation of PLCδ, which functions the same way as PLCβ to 
hydrolyse PIP2 (Vriens et al. 2009; Smutzer & Devassy 2016). Due to the dependence of TRPV1 on 
PIP2 to function as an integral membrane protein and its sensitivity to the membrane and 
phospholipid environment, the depletion of PIP2 decreases TRPV1 activity and results in 
desensitisation (Lukacs et al. 2013a; Rohacs 2015; Smutzer & Devassy 2016). This suggests that 
activation of TRPV1 may be self-limiting. This is so, as second messenger systems that result from 
TRPV1 activation decrease PIP2 concentrations within the plasmalemma via PLC hydrolysis, thus 
regulating TRPV1 activity (Lukacs et al. 2013b). In contrast, in vitro activation of TRPV1 by 
capsaicin continues in the absence of PIP2 (Cao et al. 2013b; Cao et al. 2013a; Senning et al. 2014). 
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However, the reintroduction of PIP2 into the membrane induces subsequent desensitisation of the 
TRPV1 (Cao et al. 2013b; Cao et al. 2013a; Senning et al. 2014). This suggests that TRVP1 activity 
may be modulated by PIP2 depending on what side of the plasmalemma it is found. Hence, further 
studies are needed to confirm if prolonged activation by capsaicin in vivo is a self-limiting process, 
as this may have consequences for the therapeutic use of capsaicin, in particular, for long-term 
capsaicin usage in treating obesity and metabolic syndrome. 
1.5 Capsaicin as a treatment in pathophysiological disease states  
The role of capsaicin in analgesia and TRPV1 physiology has been established. Additionally, 
TRPV1 expression is abundant throughout the body. Inoue et al. (2006) using reverse transcriptase 
polymerase chain reaction (RT-PCR) established the distribution of TRPV1 in different cells and 
tissues, including smooth muscle cells and endothelial cells found in the cardiovascular system. 
Hence the role of capsaicin in cardiovascular and other disease states will be explored. 
1.5.1 Hypertension and renal function  
Capsaicin-induced activation of TRPV1 results in the cytosolic Ca
2+
-induced release of substance P 
and CGRP, which produces vasodilatation, thus decreasing blood pressure and relieving 
hypertension (Li & Wang 2003; Fattori et al. 2016). Since TRPV1-containing afferents are 
intricately associated with the cardiovascular system (Tominaga et al. 1998; Inoue et al. 2006), Li 
and Wang (2003) imposed a high salt intake onto Wistar rats and noted that oral low-dose capsaicin 
activated TRPV1 receptors in surrounding cardiovascular tissues. In these rats, CGRP 
concentrations increased, indicating that capsaicin induced post-synaptic release of CGRP and 
substance P. Li and Wang (2003) also treated the rats with the TRPV1 antagonist capsazepine and 
noted that the hypotensive effects of capsaicin were ameliorated. Li and Wang (2008) showed that 
TRPV1 activation in renal tissue decreased renal pressure, increased glomerular filtration rate and 
increased water/sodium excretion. Hence, Li and Wang (2008) concluded that TRPV1 activation by 
capsaicin augments CGRP and substance P release and, therefore, has a key role in mediating renal 
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function and, consequently, blood pressure. Furthermore, since capsaicin treatment improves 
glomerular filtration rate and enhances diuresis, it would be expected that creatinine, urate and urea 
concentrations would be improved in an obese rat model. While it can be appreciated that changes 
in renal function can indirectly affect blood pressure, more studies are needed to determine the 
impact capsaicin may convey on renal physiology and treatment of its pathological conditions. 
However, since renal function is a chronic mediator of blood pressure, future long-term studies 
would be of benefit to determine the effectiveness of capsaicin as a chronic treatment option (Hall 
2015) as it is unknown whether chronic capsaicin administration results in TRPV1 desensitisation 
within the kidneys and surrounding tissue, making chronic capsaicin an ineffective treatment to 
regulate renal function and blood pressure.  
TRPV1 is expressed by cells of the vascular endothelium (Inoue et al. 2006). Activation of TRPV1 
by dietary low-dose capsaicin increased nitric oxide production from endothelial cells (Yang et al. 
(2010). They postulated that oral low-dose capsaicin would activate endothelial TRPV1, increase 
cytosolic Ca
2+
, induce activation of PKA and endothelial nitric oxide synthase (eNOS), resulting in 
nitric oxide release and subsequent vasodilatation (Yang et al. 2010). Xu et al. (2011) validated this 
proposal by administering low-dose oral capsaicin to demonstrate increased eNOS concentrations, 
blood pressure reductions and reduced instances of stroke in hypertensive rats. They indicated 
TRPV1 knock-out hypertensive mice remained hypertensive and susceptible to stroke in the 
presence of capsaicin (Xu et al. 2011). Since this study measured cerebrovascular activity, it could 
be proposed that capsaicin treatment would enhance cognitive function if the cerebral blood flow 
rate was enhanced. However, further studies confirming this need to be performed. Additionally, 
further studies are needed to see whether capsaicin crosses the blood-brain barrier and stimulates 
TRPV1 expressed within the brain, as it remains controversial whether capsaicin crosses the blood-
brain barrier (Donnerer et al. 1990; Vermeersch et al. 2015).  
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Studies in the rat indicate that dietary capsaicin can reach and cross the blood-brain barrier 
(Donnerer et al. 1990; Hu et al. 2005). Human studies are yet to validate these findings. It is 
suggested that capsaicin may not cross the blood-brain barrier, but may increase the permeability of 
the blood-brain barrier by increasing CGRP release in the cerebral cortex (Vermeersch et al. 2015). 
However, there is consensus that capsaicin can reach the brain via the systemic blood flow (O'Neill 
et al. 2012). Given that the blood-brain barrier is leaky at the area postrema and median eminence, 
capsaicin may act centrally by crossing the barrier at this particular cortical region (Bauer et al. 
2016). This area is juxtaposed to the hypothalamus, which has an array of functions including the 
integration and processing of sympathetic and parasympathetic information. Hence, capsaicin may 
convey its effects centrally to induce changes in satiety, blood pressure, digestion and various 
psychological behaviours (Hall 2015). Thus, further studies involving vagotomy or vagal ablation 
in conjunction with capsaicin treatment in rats may assist in validating this hypothesis. Irrespective 
of the mechanisms involved, it is clear from these studies that TRPV1 plays a pivotal role in 
hypertension management. 
1.5.2 Atherosclerosis and inflammation  
Capsaicin may have additional effects on the human cardiovascular system other than the regulation 
and treatment of hypertension, such as decreasing lipid stores and attenuation of atherosclerotic 
lesions (Rzucidlo et al. 2007; Ambrosino et al. 2013; Robbins et al. 2013). Atherosclerosis is 
essentially an inflammatory process with excess lipid accrual in the arterial wall inducing vascular 
remodelling (Fattori et al. 2016). Vascular remodelling occurs together with vascular smooth 
muscle cell hypertrophy and hyperplasia in the medial and intimal vascular layers, the migration of 
these cells from the medial layer to the intimal layer, or both (Rzucidlo et al. 2007; Lacolley et al. 
2012; Robbins et al. 2013; McCarty et al. 2015). These changes occur due to vascular smooth 
muscle cell phenotypic switching between three phenotypes, synthetic, macrophage-like and 
osteochondrogenic, in response to stimuli including proinflammatory mediators and reactive 
species (Ambrosino et al. 2013; Salabei & Hill 2015). 
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Li et al. (2014) reported that foam cell formation is the primary contributing factor of 
atherosclerosis. Foam cells were thought to be macrophages, however new evidence indicates that 
the majority of foam cells are vascular smooth muscle cells exhibiting a macrophage-like 
phenotype (Lacolley et al. 2012; Li et al. 2014; Salabei & Hill 2015). Foam cells accumulate 
cytoplasmic droplets of cholesterol esters and triglycerides, as they express different cholesterol 
uptake receptors and reverse cholesterol transporters, such as low-density lipoprotein (LDL) 
receptor (LDLR), LDLR related protein 1 (LRP1) and ATP-binding cassette transporter A1, or 
ABCA1 (Ma et al. 2011; Li et al. 2014; Fattori et al. 2016). Furthermore, in vitro TRPV1 activation 
by capsaicin in these cells increased cytosolic Ca
2+
, reduced lipid accumulation, decreased LRP1 
expression and increased ABCA1, which all enhance cellular cholesterol efflux and reduce 
cholesterol uptake (Ma et al. 2011). Ma et al. (2011) successfully replicated and validated these in 
vitro findings in mice treated with 0.01% capsaicin administered orally in the presence of a high-fat 
diet. Therefore, since increased cytosolic Ca
2+
 activates PKA-mediated pathways and calcineurin, 
further studies are needed to determine if these factors act in concert, independently or if another 
intracellular mechanism is stimulated upon capsaicin-mediated TRPV1 activation. Further studies 
using capsaicin are needed to determine its role in inhibiting foam cell development and, 
consequently, atherosclerosis. 
Li et al. (2014) demonstrated that 0.01% dietary capsaicin relieved atherosclerosis by inhibiting 
foam cell formation and by inducing autophagy in oxidised LDL treated vascular smooth muscle 
cells. Autophagy is a self-degrading homeostatic mechanism that dismantles and recycles 
organelles and nutrients such as lipids (Li et al. 2014; Salabei & Hill 2015). Triggering TRPV1 
lowered proinflammatory mediator concentrations which led to decreased foam cell formation (Li 
et al. (2014). This project also established that capsaicin stimulated TRPV1 and induced autophagy 
through an adenosine monophosphate activated protein kinase (AMPK) signalling mechanism, 
which in the presence of reactive species such as oxidised LDL is suppressed and results in foam 
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cell formation. Hence, Li et al. (2014) concluded that foam cell migration was decreased, whilst 
autophagy was enhanced when TRPV1 was triggered by low-dose dietary capsaicin.  
Kiyan et al. (2014) validated that atherosclerosis results from decreased vascular smooth muscle 
cells autophagy, enhanced inflammation and subsequent migration of vascular smooth muscle cells 
and differentiation leading to foam cell formation. Wei et al. (2013) confirmed the importance of 
TRPV1 in regulating atherosclerosis by demonstrating TRPV1 knockout mice fed a high fat diet 
showed increased concentrations of cholesterol, cytokines and chemokines, which promoted 
formation of atherosclerotic plaques. Therefore, targeting TRPV1 with capsaicin could alleviate 
atherosclerosis and the processes that induce the condition. Furthermore, since atherosclerosis and 
hypertension increase the probability of stenosis, myocardial infarction, stroke, angina, thrombosis 
and embolism, capsaicin treatment could decrease the probability of these events. However, 
selected studies should determine if TRPV1 is an appropriate target in treating these secondary 
disease states. Additionally, future studies could consider capsaicin usage in treating thrombotic 
episodes, as this may have consequences on platelet aggregation, bleeding disorders and blood 
viscosity control. Furthermore, given that vascular smooth muscle cells and gastrointestinal smooth 
muscle cells are closely related and both possess the ability to undergo hypertrophy and 
hyperplasia, the mechanisms outlined above may be transferrable to the gastrointestinal smooth 
muscle cells (Blennerhassett et al. 1992; Hall 2015). Cells of the gastrointestinal tract also express 
LRP1 and ABCA1, thus indicating a potential role for these cells in lipid metabolism (Liu et al. 
2011; Tarling et al. 2013). Additionally, given that TRPV1-expressing afferents innervate the 
gastrointestinal tract, capsaicin administration may change gastrointestinal cell lipid metabolism 
and inflammatory bowel disorders via similar mechanisms (Inoue et al. 2006). Before these 
hypotheses can be tested, future investigations need to initially identify whether gastrointestinal 
smooth muscle cells possess the ability to phenotypically switch in the presence of inflammation in 
a manner similar to vascular smooth muscle cells.  
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1.5.3 Hepatic steatosis, obesity and metabolic dysfunction  
The chronic release of free fatty acids and proinflammatory chemokines by adipocytes induces 
hepatic dysfunction by causing chronic inflammation, hepatocyte apoptosis, enhanced fat 
deposition and hepatic insulin resistance (Kang et al. 2010; Wei et al. 2013; McCarty et al. 2015). 
This ultimately results in hepatic steatohepatitis as well as other metabolic disease states such as 
type 2 diabetes, insulin resistance, dyslipidaemia and cardiovascular disease (Kang et al. 2010; Wei 
et al. 2013; McCarty et al. 2015). Dietary low-dose capsaicin administered to mice and rats reduced 
systemic concentrations of interleukin-6 (IL6), tumour necrosis factor-α (TNFα), monocyte 
chemoattractant protein-1 (MCP1), macrophage inflammatory protein-2 (MIP2) and 
cyclooxygenase-2 (COX2), as mediators of obesity-induced inflammation (Kang et al. 2010; Wei et 
al. 2013; Borbély et al. 2015; McCarty et al. 2015).  
TRPV1 knockout mice had increased systemic concentrations of these factors, whilst mice 
expressing TRPV1 exhibited decreased concentrations when treated with a TRPV1 agonist, such as 
capsaicin (Wei et al. (2013). These factors were decreased in adipocytes when dietary low-dose 
capsaicin was administered orally in mice, together with reduced plasma concentrations of glucose, 
insulin and triglycerides (Kang et al. (2010). Wei et al. (2013) supported these findings, but 
additionally reported decreased LDL concentrations in TRPV1 active mice. These findings suggest 
that capsaicin upregulates LDLR and ABCA1, which promote cholesterol clearance, thus reducing 
dyslipidaemia (Kang et al. 2010; Ma et al. 2011; Wei et al. 2013; Li et al. 2014). Furthermore, this 
demonstrates that these inflammatory mediators block insulin receptors, thus causing glucose 
intolerance and contributing to dyslipidaemia (Kang et al. 2010; Wei et al. 2013; Borbély et al. 
2015). Capsaicin-induced TRPV1 activation alleviates this by diminishing their production, thus 
restoring glucose and lipid homeostasis (Kang et al. 2010; Wei et al. 2013). While it can be 
postulated that these effects occur in a similar mechanism, as outlined in vascular smooth muscle 
cell dysfunction, it does not account for findings such as increases in adiponectin and peroxisome 
proliferator-activated receptor gamma (PPARγ), which both function to assist in regulating glucose 
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and lipid metabolism (Kang et al. 2010; Ambrosino et al. 2013; Wei et al. 2013). Therefore, more 
studies into the mechanisms by which capsaicin alleviates these disorders need to be performed. 
However, given that these factors alleviate these symptoms, it would be expected that plasma 
cholesterol, triglycerides, glucose and insulin concentrations would decline and that liver function 
markers, such as bilirubin, would also decline and return to normal in an obese rat treated with 
capsaicin.  
Wang et al. (2012) demonstrated the effect of dietary capsaicin administered orally in ameliorating 
glucose and lipid dysregulation. They noted increased concentrations of glucagon-like peptide-1 
(GLP1) in mice fed a high fat diet concurrent with a return of glucose and lipid homeostasis when 
treated with capsaicin. GLP1 is a gastrointestinal hormone released by ileac L cells (Wang et al. 
2012). GLP1 decreased glucagon expression and upregulated insulin release (Wang et al. 2012; 
McCarty et al. 2015). Wang et al. (2012) suggested that GLP1 was released in response to Ca
2+
 
influx. Since GLP1 secretion is in response to increased plasma glucose, the stimulation of GLP1 
on the pancreas via GPCR, which potentiates TRPV1 activation, exacerbates the effects of 
glucagon downregulation and enhances the effects of insulin via the mechanisms listed previously. 
However, the exact mechanisms by which TRPV1 stimulation enhances GLP1 release have not 
been elucidated and provide a promising direct target for type 2 diabetes treatment. Furthermore, 
since vagal afferents supplying the gastrointestinal tract contain TRPV1, capsaicin may activate the 
gut-brain axis and induce central GLP1 release. Therefore, capsaicin may not only elicit a GLP1 
response in regulating glucose homeostasis, it may also elicit GLP1-induced satiation. This 
hypothesis may also be related to other satiety-related hormones such as peptide YY3-36, 
cholecystokinin, leptin, ghrelin and serotonin, given that vagal afferents act as an information 
highway linking the gut and the brain (Prechtl & Powley 1990; Berthoud et al. 1995; Bauer et al. 
2016). Hence, further studies are needed in both animal and human models to determine the effects 
capsaicin may convey in satiation, energy intake and, therefore, energy homeostasis.  
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Brown adipose tissue (BAT) is activated by capsaicin ingestion (Kawabata et al. 2009; Ono et al. 
2011). These authors suggest that TRPV1 activation by capsaicin in afferents supplying the 
gastrointestinal tract stimulate vagal nerve activity, which consequently triggers selective 
sympathetic neurons supplying BAT (Kawabata et al. 2009; Ono et al. 2011). Ludy et al. (2011) 
suggest that there is an interaction between sympathetic nervous system activity and food 
consumption whereby when this activity increases, consumption declines. Hence, enhanced 
sympathetic activity may increase satiety, thus reducing energy consumption, and increase BAT 
stimulation which, as demonstrated by Ono et al. (2011) and Kawabata et al. (2009), increases 
thermogenesis metabolism and energy expenditure. Janssens et al. (2014) demonstrated increased 
satiety, energy expenditure and hypothalamic activity in human trials with capsaicin, which 
supports the notion. However, since GLP1 concentrations increase upon capsaicin ingestion, it 
cannot be excluded from inducing satiety by indirectly regulating ghrelin and leptin concentrations, 
thus relieving hunger pains (Diepvens et al. 2007; Ludy et al. 2011). Additionally, these two 
pathways may act together. Although the mechanism has not been fully elucidated, it can be 
appreciated that these factors are important to study in relation to metabolic dysfunction and 
obesity. 
1.6 The animal model used for determining the effects of capsaicin 
The published literature identifies the complications associated with obesity and metabolic 
syndrome, using a range of animal models to study these pathophysiological changes and the 
potential capsaicin conveys in treating these changes. This project aims to use capsaicin in 
attenuating diet-induced metabolic syndrome. Hence, a valid animal model mimicking the 
pathophysiological changes associated with metabolic syndrome is required to identify treatment 
options in humans (Panchal & Brown 2011). Additionally, since obesity is the chief predisposing 
factor associated with its development, a diet incorporating the features of a modern westernised 
diet is required. The western diet is referred to as hypercaloric and highly palatable, due to large 
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quantities of simple sugars and carbohydrates, such as fructose, and saturated and trans fats, 
typically in the form of animal fats (McAllister et al. 2009; Sadowska et al. 2017). This diet has 
been linked to overeating and, therefore, contributes to the excessive energy intake that partly 
defines obesity (Sadowska et al. 2017).  
A model that incorporates a high-carbohydrate, high-fat diet comprised of fructose, condensed milk 
and beef tallow for its macronutrient and micronutrient composition and the response that this 
induces in male Wistar rats has been developed and used in a variety of studies initiated by the 
Functional Foods Research Group at the University of Southern Queensland (Panchal & Brown 
2011; Panchal et al. 2012; Diwan et al. 2013; Panchal et al. 2013). These rats developed metabolic 
complications, cardiovascular changes, hepatic dysfunction, increased organ wet weights and 
systemic inflammation. These studies have used a low-glycaemic cornstarch diet as a control diet, 
as it does not typically elicit any metabolic, structural or functional changes in male Wistar rats. 
However, it is important to note that rats do not appear to develop atherosclerosis and do not exhibit 
a notable change in plasma HDL and LDL concentrations (Chen et al. 2014). Hence, future studies 
should explore that possibility of translating this model into other animals, such as mice, which 
develop atherosclerosis and pronounced changes in plasma HDL and LDL concentrations (Ishibashi 
et al. 1994). However, this particular animal model provides a valid method to investigate the 
potential reversal effects that different therapeutic options, such as nutraceuticals may have on 
metabolic syndrome. Thus far, the Queen Garnet plum, coffee extract, olive leaf extract, cardamom, 
piperine and purple carrot juice have elicited favourable health benefits and are, therefore, identified 
as potential therapeutic agents in the treatment of the pathophysiological states associated with 
obesity and metabolic syndrome (Poudyal et al. 2010b; Poudyal et al. 2010a; Panchal et al. 2012; 
Diwan et al. 2013; Panchal et al. 2013; Bhaswant et al. 2015b; Bhaswant et al. 2015a).  
The model used in these studies is 16 weeks in length and all rats are either fed the high-
carbohydrate, high-fat diet or cornstarch diet. An intervention is introduced to experimental high-
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carbohydrate, high-fat diet and cornstarch diet groups at 8 weeks for a further 8 weeks to assess its 
efficacy in attenuating metabolic syndrome. However, it is important to note that this protocol does 
not assess the long-term efficacy and adverse effects of a treatment. Hence, future studies using this 
model should aim to extend the treatment period to assess the efficacy and adverse effects that a 
treatment may convey over an extended period. Nonetheless, this study will follow the same 
timeframe as outlined in these studies, as it provides a foundation to assess the potential efficacy 
capsaicin may convey in attenuating metabolic syndrome. 
1.7 Aim and hypotheses 
The published literature shows that low-dose dietary capsaicin may attenuate the individual changes 
in metabolic syndrome. However, this will be the first study to assess the efficacy of capsaicin in 
treating the range of changes seen in diet-induced metabolic syndrome. Therefore, the aim of this 
study is to observe whether low-dose dietary capsaicin (5mg/kg bodyweight/day) attenuates the 
pathophysiological changes of metabolic syndrome in an obese rat model. Subsequently, this will 
support studies to translate these findings to humans by undertaking human clinical trials. In 
particular, this study will determine whether low-dose dietary capsaicin can be used as an 
inexpensive and novel therapeutic agent to attenuate: 
 Biomarkers of obesity, which include fat mass, abdominal circumference, body mass index 
(BMI) and systemic tissue inflammation; 
 Impaired cardiovascular structure and function, defined as hypertension, increased diastolic 
stiffness within the heart, increased collagen deposition and myocardial wet weight; 
 Reduced metabolic function, defined as glucose intolerance, dyslipidaemia and an increased 
energy intake; and 
 Non-alcoholic fatty liver disease, defined by increased fat vacuole deposition, inflammatory 
cell infiltration, liver wet weight and plasma activities of liver function enzymes. 
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It is hypothesised that: 
 Low-dose dietary capsaicin will not alter physiological responses in rats fed the cornstarch 
diet. 
 Low-dose dietary capsaicin will attenuate the cardiovascular, liver, metabolic and 
inflammatory changes in rats fed a high-carbohydrate, high-fat diet. 
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Chapter 2:  Methods and materials 
2.1 Materials 
Chillies, usually from lal mirch and cayenne cultivars belonging to Capsicum annum species, were 
purchased from the local Indian grocery store at the Uni Plaza Shopping Centre, Darling Heights, 
QLD, Australia. Beef tallow was purchased from Carey Brothers, Warwick, QLD, Australia. 
Condensed milk was purchased from Coles Kearney Springs, Toowoomba, QLD, Australia. Meat-
free powdered rat food was purchased from Speciality Feeds, Glen Forrest, WA, Australia. Hubble, 
Mendel and Wakeman salt mixture was purchased from MP Biomedicals, Seven Hills, NSW, 
Australia. Fructose was purchased from Tate & Lyle, Wacol, QLD, Australia. Corn starch was 
purchased from Agri Food Ingredients, Kew East, VIC, Australia. All laboratory chemicals were 
purchased from Sigma-Aldrich Australia, Castle Hill, NSW, Australia, unless otherwise specified at 
their first appearance in text. 
2.2 Capsaicin extraction 
Initially, 740 g of chillies were dried at 65°C in a fan-forced oven for 24 hours. Chilli seeds were 
removed and chillies were subsequently crushed into smaller pieces using a domestic Kenwood 
food processor. Approximately 90 g of the chilli flakes were placed into the extraction shell of a 
Soxhlet extractor (B34). Analytical grade methanol (350 mL, Lab-Scan Analytical Sciences, 
Bangkok, Thailand) was placed into a round-bottom volumetric flask suspended in 500 mL of 
synthetic ultra-grade vacuum-pump oil (Edwards, Mississauga, Ontario, Canada), which was heated 
to 240°C by a Velp Scientific ARE heating and magnetic stirrer (Rowe Scientific, Perth, WA, 
Australia) to induce the methanol to percolate (boil and reflux) through the sample (Ashwini et al. 
2015b). The time of each cycle (boil and reflux) was measured for each run of 100 g of chillies. At 
least 15-20 cycles per run were performed as previously described (Goci et al. 2014; Ashwini et al. 
2015b). Eight Soxhlet extraction runs were performed in total with approximately 90 g of chillies 
used per run. 
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Upon completion of the Soxhlet extraction process, the contents of the round-bottom volumetric 
flask (methanol containing extract) were removed and placed on to a Laborota 4000 rotary 
evaporator to evaporate the methanol from the flask (Betts 1999). The contents of the flask were 
mixed with 100mL of analytical grade dichloromethane (Honeywell Burdic and Jackson, 
Muskegon, MI, USA), in which the capsaicin is readily soluble (Wagner & Bladt 1996; Oliveira et 
al. 2004). This mixture along with 100 mL of water was placed into a 1L separatory funnel. The 
water was added to remove any water-soluble products that may have been extracted from the 
chillies (Ashwini et al. 2015b). The contents of the flask were mixed and the water and 
dichloromethane mixtures were separated until the dichloromethane mixture was clean and free of 
water.  
Sodium hydroxide solution (0.25 M; 5g of anhydrous NaOH pearls/500mL of distilled water; 
Sigma-Aldrich Australia, Sydney, NSW, Australia) was prepared and 100 mL of the solution was 
placed with the dichloromethane layer into the 1L separatory funnel. The sodium hydroxide was 
added to remove any oil, fat and mineral products that may have been extracted from the chillies 
and that are readily soluble in its presence (Wagner et al. 2011). The contents of the flask were 
mixed and the sodium hydroxide and dichloromethane layers were separated until the 
dichloromethane mixture was clean and free of sodium hydroxide. 8 mL of analytical grade 32% 
hydrochloric acid (BIOLAB, Clayton, Vic, Australia) was added to the sodium hydroxide layer to 
neutralise the sample and this was mixed with the dichloromethane layer in the 1L separatory 
funnel. The neutralised and dichloromethane layers were mixed and separated out until the 
dichloromethane mixture was clean and free of the neutralised blend (Wagner et al. 2011; Ashwini 
et al. 2015b). The final dichloromethane layer was decanted into a pre-measured round-bottom flask 
and this flask was placed onto the rotary evaporator to evaporate the dichloromethane from its 
contents. The residual product in the round-bottom flask and the flask itself were measured to 
determine the quantity of capsaicin extracted. The product was then transferred to a pre-measured 
glass vial and the vial and its contents were measured to verify the quantity of capsaicin extracted. 
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This vial was kept under locked storage as per instructions outlined in its Material Safety Data 
Sheet.  
The presence of capsaicin was demonstrated by proton nuclear magnetic resonance spectroscopy 
(
1
H-NMR). This procedure was performed by Dr Robert Reid at the Institute of Molecular 
Bioscience, The University of Queensland. A 5 mg sample of the extract was dissolved in 0.5-1 mL 
of deuterated chloroform and placed into a 
1
H-NMR tube. 
1
H-NMR spectra were recorded at 
600.13MHz using a Bruker Avance spectrometer (Karlsruhe, Germany). Eight scans of 32K data 
points were attained at 298K using a spectral width of 10303Hz (10ppm), acquisition time of 2.28 
seconds, relaxation delay of 20 seconds, flip-angle of 90° and pulse duration of 20 microseconds 
(Reid et al. 1996; Nazari et al. 2007). 
An approximate percentage of the compounds isolated in the extract was calculated. This was 
performed by identifying recognisable peaks in the 
1
H-NMR of pure capsaicin and 
dihydrocapsaicin that occur at different chemical shifts and the relative integrated peak intensities 
were compared (Wagner et al. 2011). More specifically, the doublet of the isopropyl group of 
capsaicin and dihydrocapsaicin, which occurs approximately between 1.00 parts per million (ppm) 
and 0.80 ppm, were used to approximate the relative quantities of the obtained extract  (Yao et al. 
1994; Wagner et al. 2011). The recognisable peak areas for capsaicin and dihydrocapsaicin were 
matched against their respective standard curve to estimate their approximate percentages within 
the extract. The approximate percentage of capsaicin (% capsaicin) was determined by [(area of 
capsaicin)/(area of capsaicin + areas of unknown)]x100 (Yao et al. 1994; Wagner et al. 2011). 
2.3 Rats, experimental groups and housing 
All experimental protocols were approved by the Animal Ethics Committee of the University of 
Southern Queensland (project number – 15REA006, valid from 22/08/2016 until the 22/10/2018) 
under the guidelines of the National Health and Medical Research Council of Australia. Male 
Wistar rats (8-9 weeks old; 338 ± 7 g, n = 47) were purchased from the Animal Resource Centre, 
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Murdoch, WA, Australia. Rats arrived three weeks prior to commencing their diets and were 
acclimatised for three weeks on laboratory chow diet. One rat was found to possess a malocclusion 
and was euthanased by the University of Southern Queensland Animal Welfare Officer. The rats 
were randomly divided into four experimental groups: corn starch diet-fed rats (C; n = 11), corn 
starch diet-fed rats supplemented with capsaicin (CC; 0.015% of diet; n = 12); high-carbohydrate, 
high-fat diet-fed rats (H; n = 12) and high-carbohydrate, high-fat diet-fed rats supplemented with 
capsaicin (HC; 0.015% of diet; n = 12). 
C and H rats were fed with cornstarch and high-carbohydrate, high-fat diets, respectively, for 16 
weeks. CC and HC rats were also fed with cornstarch and high-carbohydrate, high-fat diets, 
respectively, for 16 weeks with the diets supplemented with capsaicin (0.015% of diet) for the last 8 
weeks of the protocol. The cornstarch and high-carbohydrate, high-fat diets have been previously 
described in detail, and are included in Table 3 (Panchal et al. 2011). Drinking water for H and HC 
rats was supplemented with 25% fructose, whereas C and CC rats were given drinking water 
without any additive. All rats were individually housed in temperature-controlled (21 ± 2ºC) 12-
hour light/dark cycle conditions within the animal house at the University of Southern Queensland, 
Toowoomba campus and were given ad libitum access to diet and water. 
Table 3: Composition of diet 
Components (g/kg) C H 
Corn starch 570g - 
Fructose - 175g 
Condensed milk - 395g 
Beef tallow - 200g 
Salt mixture 25g 25g 
Powdered rat food 155g 155g 
Water 250mL 50mL 
Drinking water No additives 25% fructose (w/v) 
Reference: (Panchal et al. 2011) – modified. 
2.4 Daily measurements 
Daily measurements of body weight and food and water intake were taken, which permitted the 
monitoring of the day-to-day health of the rats. The bedding of the rats was assessed on a regular 
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basis and changed when required to ensure a clean and hygienic environment was maintained. 
Energy densities of the C and H diets were used to calculate energy consumption of the rats and 
feed conversion efficiency (%) was calculated as [mean body weight gain (g)/daily energy intake 
(kJ)] x 100 (Novelli et al. 2010). 
2.5 Systolic blood pressure  
Systolic blood pressure of rats was measured at 0, 8 and 16 weeks under light anaesthesia with 
Zoletil (tiletamine 10 mg/kg, zolazepam 10 mg/kg, intraperitoneal; Virbac, Peakhurst, NSW, 
Australia), using an MLT1010 Piezo-Electric Pulse Transducer (ADInstruments, Sydney, Australia) 
and inflatable tail-cuff connected to an MLT844 Physiological Pressure Transducer 
(ADInstruments, Sydney, Australia) and PowerLab data acquisition unit (ADInstruments, Sydney, 
Australia) (Panchal et al. 2011). A pressure meter was used to calibrate the transducer on the day of 
measurement and was conducted as per manufacturer’s instructions. Room temperature was set to 
25ºC prior to the sedation procedure. Once sedated, the tails of the rats were inserted through the 
tail cuff and the transducer was wrapped around the tail alongside the cuff. Five to six individual 
systolic blood pressure readings were recorded for each rat and the mean was calculated for each rat 
prior to using the measurement for group recordings. 5mL of saline was administered 
subcutaneously following the systolic blood pressure measurements to avoid dehydration. Prior to 
the rats being returned to their individual housing, recovery of the rats from anaesthesia was 
monitored every fifteen minutes for the first hour and then once every hour until complete recovery 
was ascertained.  
2.6 Body composition measurements, abdominal circumference and body length 
Body composition analyses of rats were measured at 8 and 16 weeks under light anaesthesia using 
Zoletil (tiletamine 10 mg/kg, zolazepam 10 mg/kg, intraperitoneal; Virbac, Peakhurst, NSW, 
Australia). Room temperature was set to 25ºC prior to the sedation procedure commencing. Body 
composition analyses were measured using a Norland XR-46 Dual-energy X-ray Absorptiometry 
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(DXA) densitometer (Norland Corp., Fort Atkinson, WI, USA). The data was analysed using the 
manufacturer’s recommended software for use in laboratory animals (Small Subject Analysis 
Software, version 2.5.3/1.3.1; Norland Corp.). 10 mL of saline was administered subcutaneously 
following the DXA measurements to avoid dehydration. Prior to the rats being returned to their 
individual housing, the recovery of the rats from anaesthesia was monitored every fifteen minutes 
for the first hour and then once every hour until complete recovery was ascertained. Abdominal 
circumference was measured at 0, 8 and 16 weeks in conjunction with body composition 
measurements. A standard measuring tape was utilised to measure abdominal circumference when 
the rats were placed in the ventral recumbent position (Panchal et al. 2011). Additionally, body 
length (nose to anus) was measured at the end of the 16 week protocol to calculate body mass index 
(BMI), determined by body weight (in grams)/[body length (in centimetres)
2
] (Novelli et al. 2010). 
2.7 Oral glucose tolerance test  
At 0, 8 and 16 weeks of the protocol, rats were deprived of all diet types for 12 hours (6pm to 6am). 
During the fasting period, fructose-supplemented drinking water in the H and HC groups was 
replaced with normal drinking water. Oral glucose tolerance tests (OGTT) were performed after 
determining overnight fasting blood glucose concentrations in tail vein blood using Medisense 
Precision Q.I.D. glucose metres (Abbott Laboratories, Belford, MA). A drop of blood from the tail 
of the rats was obtained via a prick using a 30 gauge needle, which was subsequently transferred 
onto a glucose strip (Freestyle Optimum Blood Glucose Test Strips, Abbott Diabetes Care Ltd., 
Witney, Oxon, UK) attached to the glucometer. Following this, rats were administered a glucose 
load of 2 g/kg body weight as 40% glucose solution via oral gavage and blood glucose 
concentrations were measured again at 30, 60, 90 and 120 minutes post oral glucose administration 
(Panchal et al. 2011). The area under the curve was calculated by plotting blood glucose 
concentrations against time over the 120 minute period. Rats recommenced their specific diets 
following completion of the OGTT. 
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2.8 Euthanasia and isolated Langendorff heart preparation  
Rats were euthanased with Lethabarb (pentobarbitone sodium, 100 mg/kg, intraperitoneal; Virbac, 
Peakhurst, NSW, Australia). After euthanasia, heparin (200 IU) was injected through the right 
femoral vein. The abdomen was opened and blood (~5 mL) withdrawn from the abdominal aorta, 
collected into heparinised tubes and centrifuged at 5000 x g for 15 minutes to obtain plasma. 
Plasma was stored at -20ºC for further biochemical analysis. Hearts were removed and used in 
isolated Langendorff heart preparations to assess left ventricular function of the rats. Hearts isolated 
from rats were perfused with modified Krebs-Henseleit bicarbonate buffer containing (in mmol/L): 
NaCl, 119.1; KCl, 4.75; MgSO4, 1.19; KH2PO4, 1.19; NaHCO3, 25.0; glucose, 11.0; and CaCl2, 
2.16. Buffer was bubbled with 95% O2–5% CO2 and maintained at 35ºC. Isovolumetric ventricular 
function was measured by inserting a latex balloon catheter into the left ventricle connected to a 
Capto SP844 MLT844 physiological pressure transducer and Chart software on a Maclab system. 
Left ventricular end-diastolic pressure values were measured during pacing of the heart at 250 
beats/minute using an electrical stimulator. End-diastolic pressures were obtained from 0 to 30 
mmHg for calculation of diastolic stiffness constant (, dimensionless) (Panchal et al. 2011). 
2.9 Organ weights 
Upon completion of cardiac perfusion studies, hearts (n = 10 from each group) were divided into 
right ventricle and left ventricle (with septum) and weighed. Livers (n = 8-12 from each group) 
were removed and weighed. Retroperitoneal, epididymal and omental abdominal fat pads were 
removed individually and weighed. These organ weights were normalised against the tibial length 
(50.5 ± 0.8mm) at the time of organ removal and expressed as mg/mm of tibial length (Panchal et 
al. 2011). The weights of the various fat pads were substituted into the following formula to 
determine visceral adiposity index (%): ([retroperitoneal fat (g) + omental fat (g) + epididymal fat 
(g)]/[body weight (g)]) x 100 (Panchal et al. 2011). 
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2.10 Thoracic aorta organ bath 
Once the heart was removed and blood collected for biochemical analyses, the thoracic aorta was 
removed and excess adipose tissue was removed from the thoracic aorta to expose the underlying 
tissue. Thoracic aortic rings (~4 mm in length) were suspended in an organ bath filled with Tyrode 
physiological salt solution bubbled with 95% O2–5% CO2 maintained at 35ºC and the rings were 
allowed to stabilise at a resting tension of ~10 mN. The Tyrode physiological salt solution contains 
(in mmol/L):  NaCl, 136.9; KCl, 5.4; CaCl2, 1.8; MgCl2.H2O, 1.05; NaH2PO4.H2O, 0.42; NaHCO3, 
22.6; ethylenediamine-tetraacetic acid (EDTA), 0.05; ascorbic acid, 0.3; glucose, 5.5. Cumulative 
concentration response curves (contraction) were obtained for noradrenaline (Sigma-Aldrich 
Australia, Sydney, NSW, Australia) and cumulative concentration-response curves (relaxation) 
were obtained for acetylcholine (Sigma-Aldrich Australia) and sodium nitroprusside (Sigma-
Aldrich Australia) following submaximal (~70%) contraction to noradrenaline (Panchal et al. 
2011). 
2.11 Ileum and colon organ bath 
Approximately 1-2 cm long distal ileum and distal colon pieces were suspended in an organ bath 
filled with Tyrode physiological salt solution bubbled with 95% O2–5% CO2 and maintained at 
35ºC and allowed to stabilise at a resting tension of ~10 mN. Concentration response curves were 
obtained for acetylcholine by measuring responses to individual concentrations of acetylcholine.  
2.12 Tissue histology  
Two rats per group were taken exclusively for histological analysis. Two slides were prepared per 
tissue specimen and two random, non-overlapping fields per slide were taken to avoid biased 
analysis. Organs were collected from rats used for Langendorff perfusion studies. 
Immediately after removal, heart and liver were fixed in 10% neutral buffered formalin and then 
dehydrated and embedded in paraffin wax. Thin sections (5μm) of tissues were cut and stained with 
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haematoxylin and eosin stain for determination of inflammatory cell infiltration and fat vacuole 
enlargement with 20× objective (Panchal et al. 2011). Collagen distribution was defined in the heart 
with picrosirius red stain. Laser confocal microscopy (Zeiss LSM 510 upright Confocal 
Microscope) with colour intensity quantitated using the National Institutes of Health (NIH) Image 
software (NIH, Bethesda, MD, USA) was used to determine the extent of collagen deposition in 
tissue sections (Panchal et al. 2011).  
2.13 Biochemical analysis 
Plasma activities of alanine transaminase (ALT) and aspartate aminotransferase (AST), and plasma 
concentrations of total cholesterol, triglycerides, non-esterified fatty acids (NEFA) were determined 
as previously described (Panchal et al. 2011). These variables were measured using kits and 
controls supplied by Olympus (Tokyo, Japan) using an AU 400 Olympus analyser at the School of 
Veterinary Sciences, the University of Queensland, Gatton campus. NEFA in plasma was 
determined using a commercial kit (Wako Diagnostics, Osaka, Japan) and plasma concentrations of 
insulin were measured using commercial kits according to manufacturer-provided standards and 
protocols at the School of Veterinary Sciences, The University of Queensland, Gatton campus 
(Panchal et al. 2011). 
2.14 Statistical analysis 
All data are presented as mean ± standard error of the mean (SEM). Results were tested for variance 
using Bartlett’s test and variables that were not normally distributed were transformed (using log 10 
function) prior to statistical analyses. All the groups were tested for effects of diet, treatment and 
their interaction by two-way analysis of variance. When the interactions and/or the main effects 
were significant, then the groups were compared using the Newman-Keuls multiple comparison 
post-test. A P<0.05 was considered statistically significant. All statistical analyses were performed 
using Prism version 6.00 for Windows (Graphpad Software, San Diego, CA, USA).  
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Chapter 3:  Results 
3.1 Capsaicin extraction and purification 
Crude extract of capsaicin from dried chillies from cultivars of Capsicum annum species was 
obtained by using methanol as a solvent to percolate through a Soxhlet extractor. A summary of this 
procedure is given in Table 4. The crude extract was then subjected to a rigorous cleaning process 
to purify the capsaicin extract, as outlined in section 2.2 capsaicin extraction. The final product was 
a dark red oily extract. The final weight of extract is given in Table 5. Finally, the presence of 
capsaicin was determined by 
1
H-NMR spectroscopy, which provided structural evidence about the 
compounds obtained by extraction following chemical treatment and clean-up (Figure 6A). The 
presence of dihydrocapsaicin and remnant dichloromethane as the solvent was also determined. The 
protons producing the different spectral peaks are defined as follows:  
 Capsaicin – 1.10-1.20ppm = 14- and 15-CH3; 1.70-2.30ppm = 11-, 12- and 13-CH2; 2.70-
2.80ppm = 2 unrelated groups 9,10; 3.70ppm = 8-OCH3; 4.30ppm = 7- benzylic CH2; 5.30-
5.40ppm = 5,6 two doublets (double bond); 5.70ppm = NH; 5.80ppm = 4- aromatic OH; 
6.80ppm = 1-3 aromatic protons;  
 Dihydrocapsaicin – 0.80-0.90ppm = 14- and 15-CH3; 1.80ppm-2.3ppm = 9-13 CH2; 
2.70ppm = 8-OCH3; 3.9ppm = 7- benzylic CH2; 4.10-4.30ppm = 2 unrelated groups, 5,6; 
5.70ppm = NH; 5.80ppm = 4- aromatic OH; 6.80ppm = 1-3 aromatic protons; and  
 Dichloromethane – 5.30ppm, single peak.  
An approximate percentage of the compounds isolated in the extract were calculated (Table 5). This 
was performed by identifying recognisable peaks in the 
1
H-NMR of capsaicin and dihydrocapsaicin 
that occur at different chemical shifts and the relative integrated peak intensities were compared 
(Figure 6B).   
37 
 
Table 4: The number of cycles and cycle times per Soxhlet extraction run to obtain crude 
capsaicin extracts from dried chillies. 
Run 
number 
Dried chilli 
quantity (g) 
Start time 
(24hr) 
Finish time 
(24hr) 
Run time 
(hrs)  
Number of cycles 
(boil and reflux) 
Average cycle time 
(min) 
1 120 10:40:00 19:45:00 9:05 21 26 
2 65 14:33:00 07:10:00 16:37 20 21 
3 100 12:05:00 06:35:00 18:30 25 44 
4 60 17:17:00 06:50:00 13:33 24 33 
5 95 10:25:00 19:50:00 9:25 17 33 
6 110 12:20:00 11:00:00 22:40 24 55 
7 90 10:20:00 19:25:00 9:05 23 23 
8 100 13:15:00 11:00:00 21:45 21 60 
Average 93 12:37:00 12:42:00 15:08 22 37 
SEM 6 N/A N/A 3 1 5 
N 8 8 8 8 8 8 
 
Values are mean ± SEM, n=8. 
Table 5: The weight of capsaicin obtained per clean-up round and the final yield and weight of 
capsaicin obtained  
Run Number Clean-up round Vial weight (g) Vial weight + capsaicin (g) Capsaicin obtained (g) 
1 
2 
1 84.50 85.30 0.80 
3 
4 
5 
2 91.14 93.02 1.88 
6 
7 
3 86.63 93.38 6.75 
8 4 86.73 87.79 1.06 
Total capsaicin obtained (g) 10.49 
Total capsaicin yield (%) 1.42 
Approximate capsaicin ratio determined by 
1
H-NMR (%) 86 
Approximate dihydrocapsaicin ratio determined by 
1
H-NMR (%) 14 
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Figure 6a:  The structural identification of capsaicin by 1H-NMR. A 5mg sample of the extract was dissolved in 0.5-1 mL of deuterated chloroform 
and placed into a 1H-NMR tube. 1H-NMR spectra were recorded at 600.13MHz using a Bruker Avance spectrometer. Eight scans of 32K data points 
were attained at 298K using a spectral width of 10303Hz (10 ppm), acquisition time of 2.28 seconds, relaxation delay of 20 seconds, flip-angle of 90° 
and pulse duration of 20 microseconds.  
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Figure 6b:  Percentage estimation of capsaicin in purified extract by 1H-NMR. The doublet of the isopropyl group of capsaicin and dihydrocapsaicin, 
which occurred at 1.20 ppm and 0.80 ppm were used to approximate the relative quantities of the obtained extract. The recognisable peak areas for 
capsaicin and dihydrocapsaicin were matched against their respective standard curve to estimate their approximate percentages within the extract. 
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peak 
Dihydrocapsaicin 
peak 
Dichloromethane 
peak 
40 
 
3.2 Physiological variables 
The body weight and energy consumption of H rats were higher than the C rats both after 8 and 16 
weeks. Body weight and energy intake were reduced by capsaicin in both CC and HC rats 
compared to C and H rats, respectively (Table 6). H rats consumed less food than C rats, and 
capsaicin treatment reduced food intake by approximately 30% in both CC and HC groups, 
respectively. There was no change in water consumption in the experimental and control groups. 
Hence, capsaicin had no effect on decreasing the energy intake found in the 25% fructose water 
solution. This indicates that capsaicin treatment reduces food consumption and, therefore, overall 
energy intake (Table 6 and Figure 7).  
BMI and feed efficiency were higher in H rats than C rats. Capsaicin treatment improved feed 
efficiency in both HC and CC groups compared to H and C rats respectively. Capsaicin intervention 
lowered BMI in both HC and CC rats by 16% and 8% when compared to H and C rats, 
respectively. H rats gained more weight than their C counterparts during the 16 week protocol. 
Capsaicin treatment lowered the weight gained during the intervention period between weeks 8 and 
16 by 92% in CC rats and 33% in HC rats. This indicates that capsaicin improves feed efficiency 
and reduces BMI and the weight gained, independent of the diet consumed.  
Capsaicin intake was dependent on the quantity of food ingested, as it was placed in the food, thus 
permitting oral administration. Since CC rats consumed more food than HC rats, capsaicin intake 
was greater in CC rats (13.29±0.33 mg/kg body weight daily) than in HC rats (7.29±0.31 mg/kg 
body weight daily).  
3.3  Body composition analysis 
Abdominal circumference and fat pad weights were higher in H rats compared to C rats. Capsaicin 
treatment normalised abdominal fat deposition and prevented the increase in abdominal 
circumference in HC rats, as well decreasing abdominal fat deposition and circumference in CC rats 
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(Table 4). All components of abdominal fat (retroperitoneal, omental and epididymal fat pads) 
increased in H rats compared to their C counterparts, whilst capsaicin treatment reduced fat 
deposition in these areas in both the HC and CC groups when compared to H and C groups 
respectively. Hence, capsaicin treatment reduced abdominal fat deposition and, therefore, 
abdominal circumference measurements. Additionally, dorsal brown fat pads were compared in the 
different groups. Brown fat was higher in H rats compared to C rats. Capsaicin treatment did not 
change brown fat in either of the groups. 
A dual-energy X-ray absorptiometer (DXA) was used to measure bone mineral content, bone 
mineral density, lean mass and fat mass of the rats. Total body fat mass was higher in H rats when 
compared to C rats. Capsaicin treatment lowered total body fat mass in both the HC and CC groups 
respectively. Lean mass was higher in H rats compared to C rats but capsaicin intervention did not 
change body lean mass. Additionally, bone mineral content and density were increased in the H rats 
compared to C rats. Capsaicin treatment did not change bone mineral density or content. 
Kidney and spleen wet weights are given in Table 4. Wet weight increased for these organs in H 
rats compared to C rats. Capsaicin intervention did not alter the wet weights of these organs.
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Figure 7: Effects of capsaicin on water intake (A), food intake (B) and body weight (B) in C, CC, H and HC rats over 16 weeks. Values are mean ± 
SEM, n=8-12. Means without a common letter differ, P<0.05. C, cornstarch diet-fed rats; CC, cornstarch diet-fed rats supplemented with capsaicin 
(13.3 mg/kg body weight/day); H, high-carbohydrate, high-fat diet-fed rats; HC, high-carbohydrate, high-fat diet-fed rats supplemented with capsaicin 
(7.3 mg/kg body weight/day). 
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Table 6: Effects of capsaicin on physiological variables and body composition 
       P value   
Variable C CC H HC Diet Treatment  Interaction  
Physiological variables        
Feed efficiency, g/kJ 0.11±0.01
 c
 0.05±0.01
 d
 0.33±0.02
 a
 0.29±0.02
 b
 <0.0001 0.0074 0.3526 
Energy intake, kJ/day 518±14
 c
 408±10
 d
 725±17
 a
 584±14
b
 <0.0001 <0.0001 0.2524 
Capsaicin intake, mg/kg body weight/day N/A 13.29±0.33
 b
 N/A 7.29±0.31
 a
 <0.0001 <0.0001 <0.0001 
Bone mineral content (8 weeks), g 11.1±0.3
 b
 10.6±0.2
 b
 14.8±0.6
 a
 13.4±0.6
 a
 <0.0001 0.266 0.2893 
Bone mineral density (8 weeks), g/cm
2
 0.175±0.002
 b
 0.170±0.002
 ab
 0.177±0.003
 a
 0.183±0.003
 a
 0.0065 0.9427 0.0325 
Total fat mass (8 weeks), g 49.1±6.7
 b
 53.9±5.0
 b
 170.5±17.9
 a
 126.5±11.6
 a
 <0.0001 0.0688 0.0255 
Total lean mass (8 weeks), g 302.4±5.5
 a
 305.0±3.4
 a
 308.7±7.5
 a
 303.7±10.2
 a
 0.359 0.07412 0.8117 
BMI, g/cm
2 
0.62±0.02
 c
 0.57±0.01
 c
 0.86±0.02
 a
 0.73±0.01
 b
 <0.0001 <0.0001 0.091 
Body weight gain, g 52±9
 c
 27±5
 d
 276±36
 a
 186±9
b
 <0.0001 0.0056 0.1230 
Abdominal circumference (8 weeks), cm 16.6±0.5
 bc
 15.5±0.1
 bc
 19.8±0.6
 a
 17.3±0.2
 ab
 <0.0001 0.4734 0.1578 
Abdominal circumference (16 weeks), cm 17.7±0.4
 c
 14.3±0.1
 d
 24.3±0.5
 a
 19.0±0.2
 b
 <0.0001 <0.0001 <0.0001 
Visceral adiposity (16 weeks), % 5.63±0.45
 c
 3.21±0.16
 d
 11.33±0.48
 a
 8.42±0.46
 b
 <0.0001 <0.0001 0.548 
Dorsal brown fat (16 weeks), g 1.07±0.13
 b
 1.36±0.11
 ab
 1.57±0.07
 a
 1.55±0.1
 a
 0.2077 0.0023 0.1493 
Tissue wet weight (16 weeks), mg/mm tibial length  
Retroperitoneal 219±22
 c
 69±11
 d
 706±67
 a
 424±31
b
 <0.0001 <0.0001 0.192 
Epididymal 116±10
c
 97±8
 d
 324±20
 a
 219±16
 b
 <0.0001 0.0008 0.0793 
Omental  116±17
 c
 71±6
 d
 315±19
 a
 204±15
 b
 <0.0001 <0.0001 0.0826 
Total abdominal fat 451±43
 c
 238±16
 d
 1345±97
 a
 847±55
 b
 <0.0001 <0.0001 0.0669 
Kidney 50.2±1.9
 b
 46.1±1.6
 b
 61.2±0.9
 a
 55.0±1.3
 a
 <0.0001 0.0575 0.7954 
Spleen 15.0±1.0
 b
 14.2±0.8
 b
 20.1±0.9
 a
 19.1±0.8
 a
 <0.0001 0.7579 0.6079 
 
Values are mean ± SEM, n=7-12. Means without a common letter differ, P<0.05. C, cornstarch diet-fed rats; CC, cornstarch diet-fed rats supplemented 
with capsaicin (13.3 mg/kg body weight/day); H, high-carbohydrate, high-fat diet-fed rats; HC, high-carbohydrate, high-fat diet-fed rats supplemented 
with capsaicin (7.3 mg/kg body weight/day). 
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Figure 8: Effects of capsaicin on total body lean mass (A), fat mass (B), bone mineral content (C) 
and bone mineral density (D) in C, CC, H and HC rats at 16 weeks. Values are mean ± SEM, n = 7-
8. Means without a common letter differ, P<0.05. C, cornstarch diet-fed rats; CC, cornstarch diet-
fed rats diets supplemented with capsaicin (13.3 mg/kg body weight/day); H, high-carbohydrate, 
high-fat diet diet-fed rats; HC, high-carbohydrate, high-fat diet diet-fed rats supplemented with 
capsaicin (7.3 mg/kg body weight/day). 
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3.4 Metabolic variables 
The effects of capsaicin on overnight fasting blood glucose concentrations and glucose sensitivity 
were tested through OGTT and presented as the area under the curve (AUC) (Figure 9A). Fasting 
basal blood glucose concentrations were higher in H rats than C rats. Capsaicin did not alter basal 
blood glucose concentration. The AUC for H rats was higher compared to C, CC and HC rats, thus 
indicating an impaired blood glucose tolerance in H rats. Capsaicin treatment reduced the AUC for 
both CC and HC rats when compared to H and C diets. Additionally, the AUC for HC rats was 
unchanged when compared to C rats (Figure 9A). Plasma concentrations of triglycerides and NEFA 
were elevated in H rats compared with C rats. There was no difference in plasma concentrations 
between H and C rats. Capsaicin treatment lowered the plasma concentrations of total cholesterol 
and triglycerides in HC and CC rats compared to H and C rats respectively (Table 7). However, 
capsaicin had no effect on plasma concentrations of NEFA. Hence, capsaicin reversed and 
normalised impaired glucose tolerance in HC rats and improved glucose utilisation in CC rats, as 
well as preventing increases in plasma concentrations of triglycerides and total cholesterol.  
3.5 Liver structure and damage 
H rats showed higher wet weight of the liver than C rats. Capsaicin treatment reduced the wet 
weight of the liver in both HC and CC groups respectively (Table 7). The effects of capsaicin on 
steatosis and inflammation in the liver are displayed in Figure 10. H rats showed considerably more 
steatosis and inflammatory cell migration than the C groups. Microscopically, there appeared to be 
minimal variation between the C and CC rats. However, capsaicin attenuated steatosis and 
decreased inflammatory cell migration in HC rats compared to H rats. Hence, capsaicin reduced the 
liver wet weight by improving hepatic structure.  
Plasma activities of AST and ALT were higher in H rats than in C rats. Capsaicin treatment 
decreased both AST and ALT plasma activities in HC rats (Table 7). Capsaicin treatment did not 
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change AST and ALT plasma activities in CC rats when compared to C rats. Hence, capsaicin 
treatment normalised plasma activities of liver damage markers. 
 
 
Figure 9: Effects of capsaicin on plasma glucose concentrations (A) and area under the curve (B) 
in C, CC, H and HC rats at 16 weeks. Values are mean ± SEM, n = 7-12. Means without a common 
letter differ, P<0.05. C, cornstarch diet-fed rats; CC, cornstarch diet-fed rats supplemented with 
capsaicin (13.3 mg/kg body weight/day); H, high-carbohydrate, high-fat diet-fed rats; HC, high-
carbohydrate, high-fat diet-fed rats supplemented with capsaicin (7.3 mg/kg body weight/day). 
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Table 7: Effects of capsaicin on plasma biochemistry and hepatic variables  
       P value   
Variable C CC H HC Diet Treatment  Interaction  
Plasma biochemistry        
Basal blood glucose concentration, mmol/L 
 
2.8±0.2
b
 2.9±0.1
b
 3.4±0.1
a
 3.2±0.1
ab
 0.0007 0.6843 0.2266 
Total cholesterol, mmol/L 2.1±0.1
a
 1.5±0.1
b
 1.9±0.1
a
 1.5±0.1
b
 0.3354 <0.0001 0.3354 
Triglyceride, mmol/L 0.6±0.1
c
 0.5±0.1
c
 2.1±0.2
a
 1.4±0.2
b
 <0.0001 0.0131 0.0572 
Non-esterified fatty acids, mmol/L 1.7±0.2
b
 1.5±0.1
b
 3.9±0.3
a
 3.8±0.5
a
 <0.0001 0.6361 0.8745 
Hepatic variables        
Liver wet weight, mg/mm tibia 230±14
 c
 202±9
 c
 399±22
 a
 294±12
 b
 <0.0001 0.0005 0.0561 
Plasma ALT, U/L 40±5
b
 35±2
b
 56±6
a
 38±2
b
  0.0255  0.0088  0.1198 
Plasma AST, U/L 109±11
b
 102±10
b
 192±27
a
 122±16
b
  0.0322 0.005  0.074  
 
Values are mean ± SEM, n=8-12. Means without a common letter differ, P<0.05. C, cornstarch diet-fed rats; CC, cornstarch diet-fed rats supplemented 
with capsaicin (13.3 mg/kg body weight/day); H, high-carbohydrate, high-fat diet-fed rats; HC, high-carbohydrate, high-fat diet-fed rats supplemented 
with capsaicin (7.3 mg/kg body weight/day).
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Figure 10: Effects of capsaicin on fat deposition and inflammation in the liver. A-D represents 
haematoxylin and eosin staining of the liver showing fat deposition (marked as ‘FV’) and 
inflammatory cells (marked as ‘IC’) (20x). C, cornstarch diet-fed rats (A); CC, cornstarch diet-fed 
rats supplemented with capsaicin (7.3 mg/kg body weight/day) (B); H, high-carbohydrate, high-fat 
diet-fed rats (C); HC, high-carbohydrate, high-fat diet-fed rats supplemented with capsaicin (13.3 
mg/kg body weight/day) (D).
FV IC 
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3.6 Cardiac structure and function 
Systolic blood pressure was measured at 0, 8 and 16 weeks and is presented in figure 11. By week 
8, H feeding increased systolic blood pressure to 150±1 mmHg in H rats and 151±2 mmHg in HC 
rats compared to 126±2 mmHg in C rats and 134±2 mmHg. At this point within the protocol, there 
were no differences in systolic blood pressure between H and HC rats. However, an 8 mmHg 
difference in systolic blood pressure was evident between CC rats and C rats, where the systolic 
blood pressure in CC rats was higher than C rats. Upon completion of the 16 week protocol, the 
systolic blood pressure of the H rats and C rats had increased from the 8 week values. However, the 
systolic blood pressure of both the HC and CC rats had declined considerably since the eighth 
week. Capsaicin exerted a greater effect on systolic blood pressure in rats that are H fed compared 
to C fed rats. Therefore, capsaicin treatment attenuated hypertension in H fed rats and improved 
systolic blood pressure in C fed rats.  
The vascular reactivity of the isolated thoracic aorta to acetylcholine, noradrenaline and sodium 
nitroprusside was measured and is shown in figure 13. There was no difference amongst all groups 
when the aorta was subjected to noradrenaline and sodium nitroprusside. There was no difference 
between H and C rats when the aorta was exposed to noradrenaline. However, HC and CC rats 
demonstrated an increased acetylcholine-induced relaxation. This increased relaxation was 
particularly apparent in the HC group when compared to the H group. Hence, capsaicin treatment 
reversed the endothelial damage caused by the H diet, thus returning vascular relaxation to normal. 
The isolated Langendorff heart preparation was used to assess the stiffness of the heart, defined by 
the left ventricular diastolic stiffness constant, κ (Figure 12C). The diastolic stiffness was increased 
in H rats compared to C rats. Capsaicin treatment lowered diastolic stiffness in HC rats when 
compared to H rats, to a value similar to C rats. There was no difference in diastolic stiffness 
between CC and C rats. The effects of capsaicin on inflammatory cell migration and collagen 
deposition within the heart are displayed in Figures 14 and 15. H rats demonstrated inflammatory 
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cell migration and collagen deposition within the heart compared to C groups. Microscopically, 
there appeared to be minimal variation between the C and CC rats. However, capsaicin attenuated 
inflammatory cell migration and reduced collagen deposition in HC rats compared to H rats. 
Additionally, H rats increased left ventricular and septum mass, as well as an increased right 
ventricular mass compared to C rats (Figures 12A and B). There were no differences between the 
mass of the right ventricle in CC and HC rats. However, capsaicin treatment decreased the mass of 
the left ventricle and septum in both CC and HC rats compared to H and C groups. Hence, capsaicin 
treatment normalised systolic blood pressure and hence stiffness of the heart, inflammatory cell 
migration and collagen deposition, which in turn, decreased the mass of the heart in the presence of 
H feeding. 
 
Figure 11: Effects of capsaicin on systolic blood pressure in C, CC, H and HC rats over 16 weeks. 
Values are mean ± SEM, n =5-10. Means without a common letter differ, P<0.05. C, cornstarch 
diet-fed rats; CC, cornstarch diet-fed rats supplemented with capsaicin (13.3 mg/kg body 
weight/day); H, high-carbohydrate, high-fat diet-fed rats; HC, high-carbohydrate, high-fat diet-fed 
rats supplemented with capsaicin (7.3 mg/kg body weight/day). 
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Figure 12: Effects of capsaicin on systolic left ventricle and septum weight (A), right ventricle 
weight (B) and diastolic stiffness (C) in C, CC, H and HC rats at 16 weeks. Values are mean ± 
SEM, n =5-10. Means without a common letter differ, P<0.05. C, cornstarch diet-fed rats; CC, 
cornstarch diet-fed rats diets supplemented with capsaicin (13.3 mg/kg body weight/day); H, high-
carbohydrate, high-fat diet diet-fed rats; HC, high-carbohydrate, high-fat diet diet-fed rats 
supplemented with capsaicin (7.3 mg/kg body weight/day).
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Figure 13:  The effect of capsaicin on noradrenaline-induced contraction (A), sodium nitroprusside-induced relaxation (B) and acetylcholine-induced 
relaxation (C) in thoracic aortic rings from C, CC, H and HC rats at 16 weeks. Values are mean ± SEM, n =5-10. Means without a common letter 
differ, P<0.05. C, cornstarch diet-fed rats; CC, cornstarch diet-fed rats diets supplemented with capsaicin (13.3 mg/kg body weight/day); H, high-
carbohydrate, high-fat diet diet-fed rats; HC, high-carbohydrate, high-fat diet diet-fed rats supplemented with capsaicin (7.3 mg/kg body weight/day). 
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Figure 14: Effects of capsaicin on collagen deposition in the heart. A-D represents picrosirius red staining of the heart showing collagen deposition 
(20x). C, cornstarch diet-fed rats (A); CC, cornstarch diet-fed rats supplemented with capsaicin (13.3 mg/kg body weight/day) (B); H, high-
carbohydrate, high-fat diet-fed rats (C); HC, high-carbohydrate, high-fat diet-fed rats supplemented with capsaicin (7.3 mg/kg body weight/day) (D). 
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Figure 15: Effects of capsaicin on inflammation in the heart. A-D represents haematoxylin and eosin staining of the heart showing inflammatory cells 
(marked as ‘IC’) (20x). C, cornstarch diet-fed rats (A); CC, cornstarch diet-fed rats supplemented with capsaicin (13.3 mg/kg body weight/day) (B); H, 
high-carbohydrate, high-fat diet-fed rats (C); HC, high-carbohydrate, high-fat diet-fed rats supplemented with capsaicin (7.3 mg/kg body weight/day) 
(D). 
A B D C 
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3.7 Gastrointestinal smooth muscle function 
In the ileum, there was no difference in acetylcholine-induced contraction between H and C rats 
(Figure 16A). However, CC and HC rats demonstrated increased contractile responses to 
acetylcholine. In the colon organ bath, there were no differences between all of the groups (Figure 
16B). Hence, capsaicin improved contractility only in the ileum.  
 
 
Figure 16:  The effect of capsaicin on acetylcholine-induced contraction in ileum (A) and colon (B) 
rings from C, CC, H and HC rats at 16 weeks. Values are mean ± SEM, n =5-10. Means without a 
common letter differ, P<0.05. C, cornstarch diet-fed rats; CC, cornstarch diet-fed rats diets 
supplemented with capsaicin (13.3 mg/kg body weight/day); H, high-carbohydrate, high-fat diet 
diet-fed rats; HC, high-carbohydrate, high-fat diet diet-fed rats supplemented with capsaicin (7.3 
mg/kg body weight/day). 
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Chapter 4:  Discussion 
4.1 Capsaicin extraction and purification 
In this study, capsaicin was first isolated from chillies and then characterised before its 
administration to rats fed either a C or H diet. The streamlined processes for the extraction and 
purification of capsaicin from various chilli cultivars generated a yield of 1.42%. A yield of 
approximately 0.5 – 2.0% from different chillies has been reported using similar procedures as in 
this study (Huang et al. 2000; Peña-Alvarez et al. 2009; Koleva Gudeva et al. 2013; Goci et al. 
2014; Ashwini et al. 2015a).  
The presence of capsaicin and an estimate of its proportion were determined by 
1
H-NMR 
spectroscopy. Protons grouped on a specific carbon or other atoms possess different resonances 
between α and β-spin states than protons on other carbon atoms, which is dependent on their given 
environments (Bertini et al. 2012; Jacobsen 2016). The distinctive structural activities convey 
different electron densities around the proton nuclei or different local magnetic environments, thus 
resulting in a unique resonance (Wagner et al. 2011; Bertini et al. 2012; Jacobsen 2016). 
Additionally, the resonance energy of a group of protons on a specific carbon atom will be coupled 
to the spin states of the protons situated on neighbouring carbons (Bertini et al. 2012; Jacobsen 
2016). This results in what is termed a ‘classical’ splitting rule (n+1), where a single or group of 
protons on a specific carbon are split into a total of (n+1) peaks, where n is the number of protons 
on carbons adjacent to the specific carbon (Bertini et al. 2012; Jacobsen 2016). Therefore, if n=0, 
the group of protons appears as a singlet; if n=1, the protons appear as a doublet; if n=2, the protons 
appear as triplet and so on. This method was used to provide structural evidence for the compounds 
in the extract. Hence, the presence of capsaicin was confirmed, as was the presence of 
dihydrocapsaicin and remnant dichloromethane as the solvent. The spectra obtained shows similar 
values to the literature that have used 
1
H-NMR spectroscopy to determine the structure of 
compounds isolated from chillies (Lin et al. 1993; Yao et al. 1994; Wagner et al. 2011). 
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This study described approximate percentages of 86% capsaicin and 14% dihydrocapsaicin in the 
final extract. This proportion resembles that of commercially sold natural capsaicin, which typically 
reports a ratio of 65-80% capsaicin to 20-35% dihydrocapsaicin (Lin et al. 1993; Yao et al. 1994; 
Betts 1999; Abdel-Salam 2014). These values were obtained from the doublet of the isopropyl 
group of capsaicin and dihydrocapsaicin, which occurred between approximately 1.10 ppm and 
0.80 ppm. These recognisable peak areas for capsaicin and dihydrocapsaicin were matched against 
their respective standard curves to estimate their approximate percentages within the extract (Yao et 
al. 1994). Higher purification values of capsaicin have been reported in the literature, ranging from 
85%-98%, where extended purification assays using high-performance liquid chromatography and 
gas chromatography–mass spectrometry have been implemented (Yao et al. 1994; Betts 1999; 
Peña-Alvarez et al. 2009). Finally, the presence of dichloromethane was expected as it is commonly 
used in other purification procedures as a solvent and its presence is typically detected (Gottlieb et 
al. 1997).  However, it is unknown what percentage of a solvent would be expected to be present 
following the purification process, as previous studies have not reported the quantity of solvents or 
artefacts present from their purification or clean-up process (Gottlieb et al. 1997; Niedzialkowska et 
al. 2016). Hence, it is not clear as to what is a common proportion of solvent observed during 
capsaicin extraction and purification, as well as the effect that the presence of a low percentage of 
solvent within an extract may convey on a biological study. 
4.2 Capsaicin dosage 
Acute high-doses of capsaicin administered orally, intraperitoneally, subcutaneously, intrathecally 
and intravenously convey detrimental effects to an animal depending on the dose, where the greater 
doses produce more serious adverse effects (Glinsukon et al. 1980; Gamse 1982; Surh & Sup Lee 
1995; Rüttimann et al. 2009; Zhang & Ritter 2012). Adverse effects include neurotoxicity, 
hormonal imbalances, inflammation, severe cardiorespiratory depression or excitation, temporary 
paralysis, cancer and death at doses of ranging from 50mg/kg to 10g/kg body weight (Glinsukon et 
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al. 1980; Gamse 1982; Surh & Sup Lee 1995; Rüttimann et al. 2009; Zhang & Ritter 2012). 
However, low-dose capsaicin administered by different administration routes, in particular the oral 
route, have demonstrated positive health outcomes and have been extensively reviewed elsewhere 
(Abdel-Salam 2014). These studies typically report a dietary dose of capsaicin equivalent of 
0.005% to 0.025% of an animal’s dietary food intake as conveying positive health benefits (Mózsik 
et al. 2005; Zvara et al. 2005; Leung 2008; Kang et al. 2010; Yang et al. 2010; Xu et al. 2011; 
Wang et al. 2014; Chen et al. 2015; Kang et al. 2016). Hence, an initial dose of 5mg/kg body 
weight/day of dietary capsaicin was proposed for this study. This equated to approximately 0.015% 
of the total daily dietary intake of rats. Therefore 0.015% of capsaicin was placed into the food, as 
outlined in section 2.3 Rats, experimental groups and housing.  
The daily dosage is proportional to the amount of food consumed by the rats. Upon the initial 
period of treatment, the amount of food being ingested did not differ from the control groups. 
However, as the protocol progressed, the amount of food ingested by the CC and HC rats 
decreased, which, in turn, meant that the dose of capsaicin decreased. Additionally, as the protocol 
progressed and the weight of the rats increased, the dose of capsaicin was reduced. The CC rats 
ingested approximately 13.3 mg/kg of body weight/day and the HC rats approximately 7.3 mg/kg of 
body weight/day, more than that initially expected. The dose ingested by HC and CC equates to 
approximately 97.2 mg/day or 1.62 mg/kg of body weight/day for a 60 kg human based on the body 
surface area rule described by Reagan-Shaw et al. (2008). This dose corresponds to the daily intake 
of capsaicin described in the rural Thai population, who report a 10.3-17.9% incidence of diet-
induced obesity, which is significantly less than westernised countries, such as Australia 
(Aekplakorn et al. 2007; Leung 2008). Hence, future studies may utilise chilli as a whole food at a 
rate as consumed by the rural Thai population to study the effects that capsaicin may convey on 
diet-induced obesity and metabolic syndrome. 
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4.3 Central obesity and the development of metabolic syndrome  
The risk factors of metabolic syndrome include central obesity, hypertension, decreased blood 
HDL, elevated fasting glucose and elevated blood triglycerides concentrations (Table 1) (Harris 
2013). These features increase the likelihood of developing non-alcoholic fatty liver disease, 
cardiovascular disease and type 2 diabetes (Harris 2013). Central obesity is the predominant factor 
leading to metabolic syndrome diagnosis in Australia (Harris 2013). Nearly half of the Australian 
adult population and over 70% of people under 17 do not meet the minimum daily physical activity 
requirements (Tolhurst et al. 2016). Over 40% of Australians acquire their daily energy intake from 
an energy-dense westernised-diet high in both saturated fats and simple carbohydrates (McAllister 
et al. 2009; Tolhurst et al. 2016). Hence, it is clear that a large part of the obesity problem in 
Australia results from an increase in energy intake compared to energy output. The protocol of this 
study not only mimics the westernised-diet by administration of the H diet, but it also provides no 
structured exercise to animals throughout the course of the 16 weeks. This animal model, therefore, 
mirrors the lifestyle that is prevalent in Australia and the associated development of obesity and 
metabolic syndrome that results from these lifestyle choices.  
Central obesity and increased body weight were evident by week 8 of the protocol. H fed rats had 
developed an increased fat mass and abdominal circumference in comparison to their C fed 
counterparts. The abdominal circumference, which is a primary marker used clinically to 
demonstrate central obesity, of the H fed rats continued to increase throughout the course of the 16 
weeks (Harris 2013). Upon completion of the protocol, the H diet successfully induced the 
metabolic syndrome, not only evidenced by central obesity, but also by hypertension, impaired 
glucose tolerance and an elevated plasma concentration of triglycerides. Consequential changes of 
diet-induced obesity were also observed, including non-alcoholic fatty liver disease, demonstrated 
by deranged biochemical markers, steatohepatitis and an increased liver wet weight; and 
cardiovascular remodelling, indicated by increased myocardial wet weight, inflammatory cell 
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migration, collagen deposition, systolic blood pressure and left ventricular diastolic stiffness, as 
well as reduced endothelial function.  
H rats also increased BMI, which is commonly used to categorise overweight and obesity. The 
increased abdominal circumference, weight gain and BMI were due to enlarged visceral adiposity 
evidenced by increased fat deposition in omental, retroperitoneal and epididymal fat pads, as well 
as an overall increase in fat mass by DXA. These markers were reduced in rats that were treated 
with low-dose dietary capsaicin. These findings are in keeping with the literature (Leung 2008; 
Kang et al. 2010; Chen et al. 2015). However, to my knowledge, this is the first study to 
demonstrate a decrease in BMI, weight, abdominal circumference, visceral adiposity, total fat mass 
and abdominal fat pad weight with low-dose dietary capsaicin in healthy subjects. 
The increase in visceral or central adiposity, rather than the general increase in adiposity throughout 
the rest of the body, is responsible for the metabolic consequences of obesity (de Souza et al. 2012). 
However, the reasons why this occurs remain elusive, as its development is multi-faceted and 
complex. Central obesity is described as an increase in adiposity, low-grade inflammation, 
increased neurogenic tone and hormonal imbalances, as well as dysbiosis (Moran & Shanahan 
2014; Bauer et al. 2016). Central obesity may result from postprandial blood flow distributing an 
increase in absorbed fat nutrients favourably to the adipose within the viscera (Leung 2008). 
Ingested fats are first sampled within the intestinal lumen prior to absorption and distribution to 
various adipose sites via the systemic circulation (Leung 2008). The intestinal lumen is lined with 
an epithelium rich in nutrient-sensing cells, such as enteroendocrine cells, which are responsible for 
initiating a majority of signalling and communication within the gut-brain axis in response to 
preabsorptive nutrients (Gribble & Reimann 2016). The apical plasmalemma of these cells are 
covered in microvilli, which open to and directly contact the luminal contents (Gribble & Reimann 
2016). Additionally, vagal fibres extend into the lamina propria of the intestinal villa, terminate at 
the basolateral plasmalemma of enteroendocrine cells and express receptors for gut hormones such 
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as ghrelin, leptin, cholecystokinin (CCK), pancreatic peptide YY3-36 (PYY) and GLP1, thus leading 
to receptor activation and subsequent neuronal stimulation (Dockray 2013; Bauer et al. 2016). 
Additionally, when food enters the stomach in the form as a bolus, the stomach becomes stretched 
and triggers a feedback-loop to the brain by vagal afferents to cease eating (Cooke & Clark 1976; 
Suzuki et al. 2012). Chronic consumption of a hypercaloric diet, in particular a diet high in fat, is 
correlated to decreased vagal sensitivity to gut peptides, chemicals and distension (Daly et al. 
2011). This results in impaired intestinal nutrient-sensing and energy homeostasis by an increased 
energy intake, thus contributing to the obesogenic state (Daly et al. 2011). It would be expected that 
these characteristics would have been prevalent in H-fed rats. 
Vagal afferents express TRPV1, commonly referred to as the capsaicin receptor (Ono et al. 2011). 
Dietary capsaicin and capsaicin analogues, such as capsiate, bind to TRPV1 expressed on vagal 
afferents and cause an influx of cytosolic Ca
2+
, thus causing neuronal excitation and activation of 
the gut-brain axis (Caterina et al. 1997; Ono et al. 2011; Hall 2015). Therefore, capsaicin may cause 
an increase in vagal firing, which results in an increased transmission of sensory information from 
the gut to the brain. The information conveyed by vagal afferents converges in the nucleus tractus 
solitarius of the dorsal vagal complex within the brainstem before being integrated and processed 
within the hypothalamus (Craig 1996; Schwartz et al. 2000). The hypothalamic arcuate nucleus 
responds to peripheral and central appetite signals via tightly-regulated neurotransmitter release 
from two separate neuronal populations, pro-opiomelanocortin and agouti-related protein neurons. 
Agouti-related protein neurons release the inhibitory neurotransmitters, agouti-related protein and 
neuropeptide Y (Cone et al. 2001; Suzuki et al. 2012; Buhmann et al. 2014). These 
neurotransmitters stimulate hunger and appetite, as well as decrease energy expenditure, thus 
contributing to excessive food consumption and weight gain (Dryden et al. 1995; Ollmann et al. 
1997; Enriori et al. 2007). However, pro-opiomelanocortin neurons in the lateral arcuate nucleus 
release pro-opiomelanocortin, which stimulates the release of α-melanocortin-stimulating hormone 
and cocaine-and-amphetamine-regulated transcript (Suzuki et al. 2012). These neurotransmitters are 
62 
 
antagonistic of agouti-related protein and neuropeptide Y and decrease appetite and hunger, thus 
inhibiting food intake, as well as increasing energy expenditure, thus contributing to weight loss 
(Cowley et al. 2001; Nakhate et al. 2011; Bauer et al. 2016). Therefore, this provides a valid 
pathway as to how capsaicin may induce its effects within the diet-induced obese rat (Figure 17). 
This study did not evaluate this neurophysiological pathway so that this pathway can only be 
theorised to provide a valid means of how capsaicin may have exerted its effects from accepted 
literature, so further studies are required to demonstrate this. However, in support of this 
mechanism are studies that have demonstrated that rats with vagal ablation or vagotomy, in addition 
to TRPV1 deficiency, do not respond to capsaicin, do not increase intracellular Ca
2+ 
concentrations, 
do not convey increased activity to the nucleus tractus solitarius or arcuate nucleus, display 
hyperphagia and an increase in weight (Rong et al. 2004; Bielefeldt & Davis 2008; Daly et al. 2011; 
Ono et al. 2011).  
Increased vagal firing within rats treated with low-dose dietary capsaicin has been correlated to 
BAT activation (Kawabata et al. 2009; Ono et al. 2011). These authors suggest that TRPV1 
activation in afferents supplying the gastrointestinal tract stimulate vagal nerve activity, which 
consequently triggers selective sympathetic neurons supplying BAT. Both studies demonstrated 
increased vagal activity and sympathetic neuron firing to BAT (Kawabata et al. 2009; Ono et al. 
2011). Ludy et al. (2011) suggest that there is an interaction between sympathetic nervous system 
activity and food consumption whereby when this activity increases, consumption declines. Hence, 
enhanced sympathetic activity may increase satiety, thus reducing energy consumption, and 
increase BAT stimulation which, as demonstrated by Ono et al. (2011) and Kawabata et al. (2009), 
increases thermogenesis, metabolism and energy expenditure. My study found that there were 
differences in food consumption and, therefore, energy intake between rats treated with low-dose 
dietary capsaicin independent of the diet consumed. However, it did not identify changes in BAT 
wet weight in rats treated with capsaicin. It would have been expected to show changes in BAT wet 
weight if there were enhanced BAT activity. Whilst a change in BAT weight was not identified, 
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BAT activity cannot be excluded from improving visceral adiposity, a decreased food intake and a 
lower energy intake. This is so, as this study did not incorporate resting energy metabolism and 
indirect calorimetry measurements. Additionally, this study did not look directly at the molecular 
physiology associated with BAT activation. Markers such as thermogenin, which are located in the 
mitochondria of BAT and responsible for the uncoupling of oxidative phosphorylation thus 
resulting in thermogenesis and increased energy expenditure, could be used in addition to BAT wet 
weight measurements to highlight BAT functionality in future studies (Kozak & Anunciado-Koza 
2008).  
 
Figure 17: Proposed pathways of mechanisms by which low-dose dietary capsaicin reduces weight 
gain and promotes weight loss. 
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4.4 Glucose impairment and satiety  
My study has demonstrated, as mentioned previously, improvements in feed efficiency and 
reductions in food consumption and therefore energy intake in both HC and CC rats. Hence, dietary 
capsaicin may exhibit its effects by increasing satiety and therefore preventing excess weight gain 
and adiposity. Additionally, dietary capsaicin attenuated the glucose intolerance in H rats and 
improved glucose tolerance in CC rats compared with C rats. These effects may result from 
enhanced vagal activity, as described above or via the release of GLP1. Dietary capsaicin 
ameliorated glucose dysregulation in conjunction with increased plasma and ileum concentrations 
of GLP1 in mice fed a high-fat diet (Wang et al. 2012). GLP1 is a gastrointestinal hormone released 
by enteroendocrine cells within the ileum, duodenum and colon 15 minutes postprandial (Elliott et 
al. 1993; Adam & Westerterp-Plantenga 2005). GLP1 binds to the GLP1 receptor, which is a GPCR 
located extensively throughout the central nervous system, gastrointestinal tract and pancreas 
(Larsen et al. 1997; Yamato et al. 1997). GLP1 subsequently decreased glucagon expression, 
upregulated insulin release and stimulated the satiety centres within the brain (Abbott et al. 2005; 
Wang et al. 2012). These effects were not observed when TRPV1 knockout mice ingest dietary 
capsaicin (Wang et al. 2012). Hence, dietary capsaicin treatment may increase satiety and improve 
glucose tolerance and utilisation via GLP1 release. However, the exact mechanism that capsaicin-
induced activation of TRPV1 stimulates GLP1 release remains elusive. It is hypothesised that GLP1 
release occurs in response to intracellular Ca
2+
 influx within vagal afferents, enteroendocrine cells 
and pancreatic β-cells, which is mediated by the activation of TRPV1 by low-dose dietary capsaicin 
(Wang et al. 2012). Further, a recent study demonstrated increased concentrations of GLP1 and 
gastric inhibitory peptide, as well as diminished ghrelin concentrations in healthy human subjects 
given low-dose dietary capsaicin (Kang et al. 2016).  However, this short-term study did not note 
any changes in satiety, food intake or glucose concentrations. Kang et al. (2016) additionally 
reported a lower concentration of lipopolysaccharide-binding protein and faecal Gram-negative 
bacteria, which are both associated with increased neurogenic tone and chronic low-grade 
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inflammation, both of which are hallmarks of obesity (Moran & Shanahan 2014). This provides 
further complexity as to how dietary capsaicin may exert its effects on satiety and glucose 
tolerance. Whilst the mechanisms involved are important to study for future endeavours, my study 
has demonstrated that low-dose dietary capsaicin treatment diminished food intake, leading to a 
decreased energy intake, thus preventing an increase in weight-gain and attenuated glucose 
intolerance. Additionally, to my knowledge, this is the first study to demonstrate both a decrease in 
food consumption and energy intake, as well as an improved glucose tolerance when low-dose 
dietary capsaicin is administered as part of a healthy diet. 
4.5 Hepatic dysfunction and plasma concentrations of triglycerides 
The chronic release of free fatty acids and adipokines such as IL6, TNFα, MCP1, MIP2 and COX2 
as well as a sustained increase in plasma triglyceride concentrations induces hepatic dysfunction 
and initiates oxidative stress by causing chronic inflammation, hepatocyte apoptosis, enhanced fat 
deposition and hepatic insulin resistance (Kang et al. 2010; Wei et al. 2013; Brown et al. 2015). 
This leads to non-alcoholic fatty liver disease, as well as other metabolic disease states such as type 
2 diabetes, insulin resistance, dyslipidaemia and cardiovascular disease (Kang et al. 2010; Wei et al. 
2013; Brown et al. 2015).  Additionally, an atherogenic lipid profile is typically present in 
conjunction with non-alcoholic fatty liver disease, with increased concentrations of triglycerides, 
NEFA and total cholesterol (Panchal et al. 2012; Brown et al. 2015). Increased free fatty acids and 
inflammatory adipokines, which result in dyslipidaemia are evident in diet-induced obese subjects 
(Cohen & Fisher 2013). Although free fatty acids and inflammatory adipokines were not measured 
in this study, markers of dyslipidaemia, including triglycerides and NEFA, were increased in H-fed 
rats. While low-dose dietary capsaicin reduced plasma concentrations of total cholesterol 
independent of diet, H-fed rats did not demonstrate an increase outside of normal physiological 
parameters in plasma concentrations of total cholesterol (Mary et al. 2006). Furthermore, since rats 
do not exhibit a notable change in HDL and LDL concentrations, it is not clear if a decrease in 
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plasma HDL concentration was evident (Chen et al. 2014). Hence, the primary marker of 
dyslipidaemia used in this study was the increased concentrations of plasma triglycerides, as one of 
the five risk factors associated with metabolic syndrome (Harris 2013).  
H-fed rats exhibited non-alcoholic fatty liver disease, shown by increased plasma liver damage 
enzymes, namely AST and ALT, increased inflammatory cell migration, steatosis and an 
augmented liver wet weight. The literature suggests that subjects with these parameters also possess 
hepatocytes with impaired plasmalemmal expression of cholesterol uptake receptors and reverse 
cholesterol transporters, thus leading to dyslipidaemia and steatosis within the liver (Kang et al. 
2010; Ma et al. 2011; Wei et al. 2013; Li et al. 2014). Additionally, increased inflammatory 
adipokines and free fatty acid concentrations block insulin receptors within hepatocytes, thus 
contributing to dyslipidaemia and glucose intolerance (Kang et al. 2010; Wei et al. 2013; Borbély et 
al. 2015). Dietary capsaicin administration decreased plasma concentrations of adipokines, free 
fatty acids, triglycerides, total cholesterol and glucose (Kang et al. 2010; Wei et al. 2013). 
Capsaicin induced an increased expression of hepatocyte cholesterol uptake receptors and reverse 
cholesterol transporters, thus promoting cholesterol and triglyceride clearance, in addition to 
relieving steatosis within the liver (Kang et al. 2010; Wei et al. 2013). Although the exact 
mechanisms involved are yet to be explored and elucidated, my study supported the literature in 
demonstrating that low-dose dietary capsaicin attenuated dyslipidaemia, exemplified by an increase 
in plasma triglyceride concentration, and glucose intolerance, by improving liver structure and 
function. Liver structure and hepatocyte damage was improved by low-dose dietary capsaicin and 
was established by decreasing plasma concentrations of AST and ALT, as well as decreasing 
inflammatory cell infiltration, fibrosis and steatosis, which, in turn, decreased the wet weight of the 
liver. Hence low-dose dietary capsaicin treatment attenuated obesity-induced non-alcoholic fatty 
liver disease. 
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4.6 Cardiovascular health 
The determinants of metabolic syndrome, that is obesity, dyslipidaemia, glucose intolerance and 
hypertension, lead to cardiovascular remodelling (Nikolopoulou & Kadoglou 2012). Additionally, 
inflammatory adipokines and free fatty acid release from abdominal fat pads are involved in 
cardiovascular remodelling (Pala et al. 2011). H-fed rats exhibited hypertension and cardiovascular 
remodelling, which was demonstrated by increased collagen deposition and inflammatory cell 
infiltration within the heart, thus leading to an increased myocardial wet weight, increased diastolic 
stiffness and an impaired response to acetylcholine, thus indicating endothelial damage. Low-dose 
dietary capsaicin treatment reversed hypertension, endothelial damage and the diastolic stiffness of 
the heart, as well as reduced inflammatory cell infiltration and collagen deposition within the heart, 
thus reducing the overall myocardial wet weight in H-fed rats. These findings support the literature 
in that low-dose capsaicin relieves hypertension and improves cardiovascular function (Yang et al. 
2010; Xu et al. 2011; Robbins et al. 2013; Wang et al. 2014). Additionally, to my knowledge, this is 
the first study that has demonstrated an improved endothelial response and reduction in systolic 
blood pressure in the presence of a heathy diet.  
The endothelial layer of the vasculature expresses TRPV1 channels (Inoue et al. 2006). Capsaicin 
activates TRPV1 in these cells and consequently increases cytosolic Ca
2+
, which signals PKA to 
activate eNOS (Yang et al. 2010; Xu et al. 2011). The activation of eNOS results in nitric oxide 
release. Nitric oxide induces potent vascular smooth muscle relaxation, which, in turn, causes 
vasodilatation and a subsequent decrease in systolic blood pressure (Yang et al. 2010; Xu et al. 
2011). Whilst the molecular mechanism as to how low-dose dietary capsaicin exerts its effects was 
not measured in this study, an improved response to acetylcholine-induced relaxation was observed. 
Acetylcholine binds to the muscarinic receptors on vascular smooth muscle cells, which 
subsequently increases nitric oxide production and induces relaxation in the endothelial layer of the 
vasculature (Tangsucharit et al. 2016). The impaired response of H-fed rats to acetylcholine 
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indicates endothelial dysfunction, whilst the improved response in low-dose dietary capsaicin 
treated rats demonstrates reversal of this damage and an increased sensitivity to nitric oxide. Hence, 
this supports the literature in how capsaicin induces its effects within the vasculature and reduces 
systolic blood pressure (Figure 18) (Yang et al. 2010; Xu et al. 2011).  
 
Figure 18: Proposed pathway of mechanisms by which low-dose dietary capsaicin relieves 
hypertension. 
TRPV1-expressing afferents are intricately associated with the cardiovascular system and, 
therefore, capsaicin may exert its effects on the vasculature via an alternative mechanism 
(Tominaga et al. 1998; Inoue et al. 2006). Capsaicin, through the activation of TRPV1, induces the 
release of CGRP and substance P in afferents supplying the vasculature, via an increase in Ca
2+ 
(Li 
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& Wang 2003; Zvara et al. 2005; Fattori et al. 2016). The increased release of these chemicals 
results in potent vasodilatation, thus decreasing pressure within the vasculature and, therefore, 
relieving hypertension (Li & Wang 2003; Zvara et al. 2005; Russell et al. 2014). Hence, the impact 
that these chemokines may have had on this study cannot be excluded. Additionally, low-dose 
capsaicin decreased renal pressure, increased glomerular filtration rate and increased water/sodium 
excretion, thus mediating renal function and, consequently, blood pressure (Li & Wang 2008). 
Hence, these mechanisms may assist in the regulation of blood pressure. Future studies could aim to 
induce impaired renal function in rats via a high-salt diet or measure renal function markers to 
investigate the long-term effects conveyed by low-dose dietary capsaicin on renal function and, 
subsequently, blood pressure.  
H-fed rats displayed increased inflammatory cell infiltration and collagen deposition within the 
heart. Increased cardiac collagen deposition is a direct marker of cardiac hypertrophy (Wang et al. 
2014). This was demonstrated by an increased wet weight of the left ventricle and septum. 
Inflammatory cell infiltration within the heart, contributes to the development of fibrosis, as their 
initial presence within the perivascular region of the heart recruits cardiac fibroblasts to produce 
collagen-1(Wang et al. 2014). This subsequently results in an increase in collagen synthesis and 
perivascular fibrosis. Inflammatory cells continue to further infiltrate the interstitial space, thus 
triggering the increased synthesis of collagen and its deposition, resulting in fibrosis extending 
between myocytes, which, in turn, results in interstitial fibrosis and an insulating effect on myocyte 
bundles (Krenning et al. 2010; Wang et al. 2016). This ultimately leads to altered electrophysiology 
and an increase in diastolic stiffness, which can be directly measured by the Langendorff heart 
(Krenning et al. 2010). Diastolic stiffness in H-fed rats was increased when compared to C-fed rats.  
Low-dose dietary capsaicin treatment reduced cardiac collagen deposition and inflammatory cell 
infiltration and, consequently, reduced the wet weight of the left ventricle and diastolic stiffness 
evident in H-fed rats. TRPV1 is expressed in afferent fibres innervating the heart, as well as in 
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myocytes and within cells of the endocardium (Zvara et al. 2005; Torres-Narváez et al. 2012). 
Capsaicin-induced activation of TRPV1 reduced fibrosis, inflammation and the diastolic stiffness in 
the heart (Zvara et al. 2005; Torres-Narváez et al. 2012; Wang et al. 2014). These capsaicin-induced 
effects are not displayed in TRPV1 knockout mice (Wang et al. 2014). Hence, TRPV1 mediates the 
effects of capsaicin within heart. 
How TRPV1 activation by capsaicin conveys its cardio-protectant effects on the heart are complex 
and varied. The influx of cytosolic Ca
2+
 within endothelial cells initiates a chain of events that 
induce the upregulation of an array of proteins and chemokines (Zvara et al. 2005; McCarty et al. 
2015). Of particular importance is the rise in eNOS expression and subsequent release of nitric 
oxide (Zvara et al. 2005; Torres-Narváez et al. 2012). The endocardium of the heart is lined with 
endothelial cells that are biologically akin to endothelial cells lining the vasculature (Hall 2015). 
Therefore, the production of nitric oxide by eNOS within these cells probably involves the same 
molecular pathway than that of the endothelial cells of the vasculature. Providing evidence to this 
notion are studies that have demonstrated a reduced expression of eNOS and nitric oxide production 
within both the arteries and the heart of rats treated with the known TRPV1 antagonist capsazepine 
(Torres-Narváez et al. 2012).  
Low-dose capsaicin increases the concentrations of CGRP within the heart (Zvara et al. 2005). 
Although increased CGRP concentrations have been correlated with reductions in cardiac 
inflammation (both cells and chemokines, such as IL6), fibrosis and hypertension, as well as 
improving inotropic and chronotropic responses, the exact mechanisms as to how it conveys its 
effects remain elusive (Muddhrry et al. 1988; Russell et al. 2014; Zheng et al. 2015). Furthermore, 
CGRP-containing neurons innervate the atrioventricular and sinoatrial nodes, as well as the 
myocardium and coronary arteries (Muddhrry et al. 1988; Ieda et al. 2006). Hence, it is 
hypothesised that CGRP, released by capsaicin-induced TRPV1 activation, exerts its effects in a 
similar manner as on the vasculature, which is ultimately to increase relaxation within myocytes 
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(Russell et al. 2014; Zheng et al. 2015). Additionally, CGRP release in response to low-dose dietary 
capsaicin at the cardiac electrical nodes may improve cardiac efficiency. Since CGRP typically acts 
to relax muscle by decreasing electrical excitability, it may improve cardiac efficiency by reducing 
the heart rate, which increases the fill-time within the cardiac chambers (atria and ventricles), 
resulting in a greater stroke volume and, therefore, cardiac output (Russell et al. 2014; Hall 2015). 
Whilst this may appear as a plausible hypothesis as to how low-dose dietary capsaicin may 
ultimately induce its cardio-protective effects, further studies would need to be performed in 
support of this. However, what is clear from this study is that low-dose dietary capsaicin treatment 
reverses the damage conferred by a hypercaloric diet, thus decreasing the likelihood of 
cardiovascular disease. 
4.7 Gastrointestinal function 
Rats treated with low-dose dietary capsaicin demonstrated improved contractility within the ileum. 
It is accepted that low-dose dietary capsaicin acts as a gastro-protective molecule and improves 
gastrointestinal function (Gy et al. 2001; Mózsik et al. 2005; Mózsik et al. 2009a). However, there 
is a gap in the literature with respect to isolated intestinal-organ baths in various species treated 
with low-dose capsaicin. This could be due to further advances in molecular testing or a large focus 
on human gastrointestinal health where it is not possible to perform isolated organ baths. Either 
way, the mechanisms by which low-dose dietary capsaicin acts a gastro-protectant remain elusive 
and somewhat controversial. The current accepted theory is that dietary capsaicin induces the 
release of CGRP via the activation of the TRPV1 receptor (Abdel-Salam 2014). CGRP is expressed 
throughout the entire central and peripheral nervous systems, where its function differs depending 
on where it is synthesised (Abdel-Salam 2014; Russell et al. 2014).  Extrinsic spinal afferents and 
vagal afferents activated by low-dose dietary capsaicin, synapse with their cell bodies in either the 
dorsal root ganglion or the nodose ganglia respectively (Holzer 2007; Evangelista 2009). These 
extrinsic nerve terminals only expressed α-CGRP and innervated gastrointestinal smooth muscle 
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layers, the myenteric plexus and the submucosal plexus (Holzer 2007; Evangelista 2009). Intrinsic 
enteric neurons of the enteric nervous system expressed β-CGRP and were localised within the 
myenteric plexus (Holzer 2007; Evangelista 2009; Abdel-Salam 2014). α-CGRP, in humans, 
directly exerted its actions on the muscle layers throughout the intestine and caused relaxation 
(Holzer 2007; Evangelista 2009; Russell et al. 2014). β-CGRP expressed by the enteric nervous 
system appears to indirectly stimulate neuronal receptors to release neurotransmitters, which, in 
turn, convey different effects on intestinal motility depending on the species (Holzer 2007; 
Evangelista 2009; Russell et al. 2014). For example, in the ileum of a guinea pig and various 
intestinal segments in other species, β-CGRP induced the release of acetylcholine, which 
subsequently activated muscarinic acetylcholine receptors in the ileum to induce a contraction 
(Someya et al. 2003; Barthó et al. 2004; Matsumoto et al. 2009). Hence, this may explain the 
improved ileum contractility observed in low-dose dietary capsaicin treated rats.  
The contrary occurs in humans, where it is accepted that both isoforms of CGRP induce 
gastrointestinal myocytes to relax (Holzer 2007; Evangelista 2009). Additionally, larger animals 
such as a human or pig, digest macronutrients, in particular fibre, to a greater extent than smaller 
animals such as a rat or guinea pig (Nyman et al. 1986). Since smaller animals, such as a rat, 
require more energy per unit of body-weight, the transit time of foodstuffs throughout the gut is 
shorter and fibre utilisation is lower (Nyman et al. 1986). Hence, it is unclear if the findings of 
increased contractility within the ileum of a rat model can be clearly correlated to humans. Hence, 
future studies could use modern molecular techniques to determine if low-dose dietary capsaicin 
initiates an increased CGRP expression throughout the gut and correlate these findings with 
changes in human gastrointestinal tract function and health. 
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Chapter 5:  Conclusions 
The primary conclusions of this study are that low-dose dietary capsaicin produced added health 
benefits to rats on a healthy diet and attenuated the signs of metabolic syndrome in diet-induced 
obese rats. Support for the first conclusion is that low-dose dietary capsaicin improved some 
physiological parameters in C-fed rats. Low-dose dietary capsaicin reduced abdominal adiposity, 
abdominal circumference and body weight in C-fed rats. Additionally, it improved glucose 
tolerance and utilisation within C-fed rats, reduced food intake and energy consumption, together 
with improved endothelial function and lowered systolic blood pressure. To my knowledge, this is 
the first study to demonstrate improved physiological parameters when low-dose dietary capsaicin 
is administered in the presence of a healthy diet. 
The second conclusion is supported by my findings that low-dose dietary capsaicin reduced central 
obesity, reversed glucose intolerance, decreased plasma concentrations of triglycerides and reduced 
hypertension, which are the physiological and biochemical changes occurring in metabolic 
syndrome, as well as alleviated non-alcoholic fatty liver disease and cardiovascular dysfunction. 
Therefore, both hypotheses of this study were accepted. 
Overall, this study demonstrated that low-dose dietary capsaicin could be used as an inexpensive 
and novel therapeutic agent to attenuate obesity and metabolic syndrome. The literature cited 
describes the effects that low-dose dietary capsaicin may have on the individual determinants of 
metabolic syndrome and the complex changes it induces molecularly and, therefore, 
physiologically. However, to my knowledge, this is the first study since the discovery of TRPV1 to 
focus on the changes low-dose dietary capsaicin induces on multiple physiological and biochemical 
parameters and targets the pathologies that drive metabolic syndrome throughout the whole body. 
Finally, this study is the first of its kind in Australia, where diet-induced obesity and metabolic 
syndrome are prevalent, to explore the effects low-dose dietary capsaicin conveys in a diet-induced 
obesity model. Hence, this study provides the foundations for future endeavours to further critically 
analyse the use of low-dose dietary capsaicin in the prevention and treatment of metabolic 
syndrome, obesity and its associated complications.
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Figure 19: Project summary of the responses to low-dose dietary capsaicin.
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Chapter 6:  Future directions 
This study developed a simple and inexpensive extraction method of obtaining a relatively high 
yield of capsaicin. Hence, future studies that use the methods outlined here to extract capsaicin may 
wish to determine the economic cost and practicality of developing this on a larger scale for 
industrial application. Future studies may also wish to use more piquant chillies than the ones 
utilised in this procedure, in order to determine if a greater yield of capsaicin could be generated.  
Because low-dose dietary capsaicin attenuated the cardiometabolic parameters in H-fed rats and 
produced health benefits in C-fed rats, future studies could determine and quantify the expression of 
different proteins, such as TRPV1, chemokines, including CGRP and GLP1, and inflammatory 
markers such as IL6 and TNFα, that are evident systemically and within specific tissues. Large 
quantities of tissue samples were collected, stored and frozen at -80ºC and fixed in formalin from 
the rats sacrificed in this protocol. Using these samples would assist in providing evidence of the 
mechanisms involved in low-dose dietary capsaicin treatment. Providing evidence of the molecular 
pathways and linking it to the literature and the outcomes generated from this study would assist in 
providing a foundation in progressing capsaicin usage into future human trials.  
Since low-dose dietary capsaicin reduced cardiac and hepatic inflammatory cell infiltration, thus 
improving cardiac structure and function, future studies could aim at exploring the use of low-dose 
dietary capsaicin as an anti-inflammatory compound in other inflammatory diseases, such as 
inflammatory bowel disease. General histology of the gastrointestinal tract, as well as mediators of 
inflammation associated with inflammatory bowel disease could be measured and assist in 
determining capsaicin’s role as a gastro-protective molecule. Adding more complexity to pathways 
and responses that low-dose dietary capsaicin may elicit is the progression made in understanding 
of the human microbiome and how microbes in this complex ecosystem influence an individual’s 
physiology and behaviours. Progress in this area is still in its early stages. However, progress with 
respect to how microbes within the human gastrointestinal tract influence an individual’s 
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physiology and behaviour has already come so far as to redescribe and re-term the gut-brain axis as 
the gut-brain-microbiota axis (Moran & Shanahan 2014). Given the intricate interactions between 
capsaicin, TRPV1 and the nervous system, there is no doubt that future studies will need to explore 
the possible influences that low-dose dietary capsaicin may have on the gut microbiota and, in turn, 
on an individual’s physiology and behaviour. Faecal samples from the rats sacrificed in this 
protocol were collected and have been frozen for future investigations.  
Legs of the rats sacrificed in this protocol have been stored in formalin. Since, low-dose dietary 
capsaicin has anti-inflammatory properties, its use in osteoarthritis may be beneficial to explore. 
Concentrations of general inflammatory markers, histological staining of the knee joints to 
determine articular cartilage degradation, osteocyte counts and subchondral bone changes using 
micro-computerised tomography could be used to determine the possible anti-inflammatory role 
low-dose dietary capsaicin conveys in relation to osteoarthritis, as our research group has recently 
reported with lauric acid in H rats (Sekar et al. 2017). 
One of the major mechanisms of regulating systolic blood pressure is kidney function. Kidney 
function was not measured in this study. Hence, improved renal function could not be excluded 
from assisting in the regulation of blood pressure. Future studies could aim to induce impaired renal 
function in rats via a high-salt diet or measure renal function markers, such as uric acid, urea, 
creatinine and estimated glomerular filtration rate, to investigate the long-term effects conveyed by 
low-dose dietary capsaicin on renal function and, subsequently, blood pressure.  
Diet-induced obesity conveys an increased risk of developing a range of diseases, including cancer. 
The H diet induced obesity and the signs of metabolic syndrome and, therefore, may act as a model 
to test various carcinomas, such as prostate cancer. A further study using the tissues from the rats 
sacrificed in this protocol aims to determine the potential anti-cancer properties that low-dose 
dietary capsaicin may convey, as in a 2016 project using curcumin with Amanda Dieckmann, Dr 
Sunil Panchal and Dr Eliza Whiteside. Since, low-dose dietary capsaicin attenuated the 
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cardiometabolic signs of metabolic syndrome, capsaicin should reduce the expression of markers 
related to the development of colon cancer, and therefore, suggest a role as a supplement with anti-
carcinogenic properties. 
This study supports the findings of other studies in identifying the potential health benefits of low-
dose dietary capsaicin and the potential to translate these findings to humans by undertaking human 
clinical trials. Hence, future studies using dietary capsaicin should aim to define a low-dose that 
would be effective in combating the pathophysiological changes of metabolic syndrome. This study 
suggests that approximately 97.2 mg/day or 1.62 mg/kg of body weight/day for a 60 kg human 
would impart potential health benefits. However, collaborations with other researchers in relation to 
the conduct of human clinical trials may be of benefit to review the dose needed to elicit the effects 
of low-dose dietary capsaicin and protocol requirements. Human clinical trials should aim to 
measure central obesity markers, blood pressure, glucose tolerance, plasma lipid profiles, in 
particular HDL and triglycerides, liver function markers, renal function markers, inflammatory 
markers and various other chemical messengers, such as CGRP and GLP1 concentrations to 
ascertain the effectiveness of low-dose dietary capsaicin in attenuating these physiological changes. 
Additionally, the differences in dyslipidaemia, in particular HDL and LDL and, therefore, 
atherosclerosis are more pronounced in humans. Hence, measuring these markers in humans would 
further demonstrate low-dose capsaicin’s efficacy in treating cardiovascular disease, which is still 
the number one cause of mortality globally, and the complex haemodynamic properties that are 
evident within this system.  
Different dosages of capsaicin have been established to be efficacious in providing pain relief by 
causing neuronal desensitisation. This effect is described in 1.4.5 TRPV1 desensitisation and 
modulation. Hence, it is unknown if prolonged use of oral low-dose dietary capsaicin would induce 
desensitisation in the gastrointestinal tract, heart or liver and, therefore, render capsaicin treatment 
ineffective. Therefore, future studies investigating the prolonged oral use of low-dose dietary 
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capsaicin administration would be of benefit. Long-term studies that investigate chronic low-dose 
dietary capsaicin use would be able to provide insight into the possible adverse effects that may 
occur. Hence, there still remains an extensive amount of research to be performed on the potential 
health benefits of low-dose dietary capsaicin.  
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